NOTE: The following Minutes are provided for informational purposes only.

If you would like to obtain an official copy of these Minutes, please contact

the State Board of Pharmacy at 614/466-4143 for instructions and fee.

STATE BOARD OF PHARMACY; 77 SOUTH HIGH STREET, ROOM 1702; COLUMBUS, OHIO 43215-6126

Tel: 614/466-4143 Fax: 614/752-4836 Eml: exec@bop.state.oh.us

Minutes Of The Meeting

Ohio State Board of Pharmacy

June 2, 3, 4, 2003

MONDAY, JUNE 2, 2003

10:00 a.m.

ROLL CALL

The State Board of Pharmacy convened in Room West-B&C, 31st Floor, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio with the following members present:

Diane C. Adelman, R.Ph. (President); Robert P. Giacalone, R.Ph. (Vice-President); Suzanne R. Eastman, R.Ph.; Elizabeth I. Gregg, R.Ph.; Lawrence J. Kost, R.Ph.; Nathan S. Lipsyc, R.Ph.; Dorothy S. Teater, Public Member; and James E. Turner, R.Ph.

Also present were Timothy Benedict, Acting Executive Director; William McMillen, Licensing Administrator; Mark Keeley, Legislative Affairs Administrator; Robert Cole, Compliance Supervisor; David Rowland, Legal Affairs Administrator; and Sally Ann Steuk, Assistant Attorney General.

10:01 a.m.

R-2003-179

Mr. Turner moved that the Board cancel the reinstatement hearing scheduled for June 2, 2003 requested by Roger Elliott as moot. Confirmation has been received that Mr. Elliott is deceased. The motion was seconded by Mrs. Gregg and approved by the Board (Aye-7/Nay-0).

10:09 a.m.

Mrs. Gregg moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code. The motion was seconded by Mr. Lipsyc and a roll call vote was conducted by President Adelman as follows: Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.

10:47 a.m.

Board Member Gregory Braylock, R.Ph. arrived.

11:39 a.m.

The Executive Session ended and the meeting was opened to the public. Mr. Rowland announced that the following settlement agreements previously approved by the Board had been signed by all parties and were now effective as of the date of the Board President’s signature:

R-2003-180

SETTLEMENT AGREEMENT WITH THE STATE BOARD OF PHARMACY (Docket No. D-021119-031) In The Matter Of: MATTHEW CHARLES CAMPBELL, R.Ph. 276 East Duquesne Street Columbiana, Ohio 44408 (R.Ph. No. 03-1-24590) This Settlement Agreement is entered into by and between Matthew Charles Campbell and the Ohio State Board of Pharmacy, a state agency charged with enforcing the Pharmacy Practice Act and Dangerous Drug Distribution Act, Chapter 4729. of the Ohio Revised Code. Matthew Charles Campbell voluntarily enters into this Agreement being fully informed of his rights afforded under Chapter 119. of the Ohio Revised Code, including the right to representation by counsel, the right to a formal adjudication hearing on the issues contained herein, and the right to appeal. Matthew Charles Campbell acknowledges that by entering into this agreement he has waived his rights under Chapter 119. of the Revised Code. Whereas, the Board is empowered by Section 4729.16 of the Ohio Revised Code to suspend, revoke, place on probation, refuse to grant or renew an identification card or enforce a monetary penalty on the license holder for violation of any of the enumerated grounds therein. Whereas, Matthew Charles Campbell is licensed to practice pharmacy in the State of Ohio. Whereas, on or about November 19, 2002, pursuant to Chapter 119. of the Ohio Revised Code, Matthew Charles Campbell was notified of the allegations or charges against him, his right to a hearing, his rights in such hearing, and his right to submit contentions in writing. Matthew Charles Campbell requested a hearing; it was scheduled and continued. The November 19, 2002, Notice of Opportunity for Hearing, as amended on April 23, 2003, contains the following allegations or charges:

(1)

Records of the Board of Pharmacy indicate that Matthew Charles Campbell was originally licensed in the State of Ohio on July 6, 2001, pursuant to examination, and is currently licensed to practice pharmacy in the State of Ohio. Records further reflect that on December 28, 2001, Matthew Charles Campbell became the Responsible Pharmacist at Salem Drug, Inc. pursuant to Sections 4729.27 and 4729.55 of the Ohio Revised Code and Rule 4729-5-11 of the Ohio Administrative Code.

(2)

Matthew Charles Campbell as the Dispensing Pharmacist and/or Responsible Pharmacist did, from August 18, 2001, to April 6, 2002, continuously failed to perform prospective drug utilization review and patient counseling, to wit: with the patient profile history before him, Matthew Charles Campbell and/or pharmacists under his control failed to review the original prescription and/or refill information for over-utilization, incorrect drug dosage and duration of drug treatment, and misuse; and Matthew Charles Campbell and/or pharmacists under his control failed to offer patient counseling when dispensing:

Rx #	Date	Drug	Strength	R.Ph.	Qty
74266 74267 74268 74321 75112 75113 75114 75115 75968 75969 75970 75971 76588	7/22/00 7/22/00 7/22/00 7/24/00 8/5/00 8/5/00 8/5/00 8/5/00 8/19/00 8/19/00 8/19/00 8/19/00 8/29/00	OxyContin prednisone methotrexate azathioprine furosemide Coumadin methotrexate OxyContin Deltasone Coumadin azathioprine OxyContin OxyContin	40 mg 10 mg 2.5 mg 50 mg 40 mg 5 mg 2.5 mg 40 mg 5 mg 5 mg 50 mg 40 mg 80 mg	JH JH JH JH BR BR BR BR BR BR BR BR JH	60 90 28 30 60 15 28 60 120 30 30 60 15
76811 76812 76813 76814 76815	9/1/00 9/1/00 9/1/00 9/1/00 9/1/00	furosemide methotrexate Coumadin Radiacare Gel OxyContin	40 mg 2.5 mg 2.5 mg 4x4 sheet 40 mg	BR BR BR BR BR	60 28 30 90 90
82872 82873 82874 82875 82876 82877	11/29/00 11/29/00 11/29/00 11/29/00 11/29/00 11/29/00	furosemide propranolol hydrochloride methotrexate azathioprine OxyContin OxyContin	40 mg 40 mg 2.5 mg 50 mg 40 mg 80 mg	BR BR BR BR BR BR	60 90 16 15 60 6
83699 83700 83701 84684 84685 84686 84687 84688	12/9/00 12/9/00 12/9/00 12/22/00 12/22/00 12/22/00 12/22/00 12/22/00	prednisone Radiacare Gel OxyContin propranolol hydrochloride Deltasone furosemide OxyContin OxyContin	10 mg 4x4 sheet 80 mg 40 mg 5 mg 40 mg 80 mg 40 mg	BR BR BR BR BR BR BR BR	30 10 28 90 60 60 12 60
86640 86641 86642 87114 87115 87512 87520 87521 87522 87643	1/20/01 1/20/01 1/20/01 1/27/01 1/27/01 2/1/01 2/2/01 2/2/01 2/2/01 2/3/01	propranolol hydrochloride furosemide OxyContin azathioprine OxyContin OxyContin warfarin sodium methotrexate quinine sulfate methadone hydrochloride	40 mg 40 mg 80 mg 50 mg 40 mg 80 mg 2.5 mg 2.5 mg 260 mg 10 mg	BR BR BR JH JH JH JH JH JH BR	90 30 20 15 30 5 30 28 30 100
88196 88197 88507 88508 88741 88742 88743 88744 89128 89129	2/10/01 2/10/01 2/14/01 2/14/01 2/16/01 2/16/01 2/16/01 2/16/01 2/22/01 2/22/01	propranolol hydrochloride OxyContin OxyContin azathioprine Prozac Pulvules Radiacare Gel methadone hydrochloride OxyContin furosemide OxyContin	40 mg 80 mg 40 mg 50 mg 20 mg 4x4 sheet 10 mg 80 mg 40 mg 80 mg	JH JH JH JH BR BR BR BR BR BR	90 15 30 15 30 90 100 15 30 24
89625 89626 89836 89837 90331 90332 90710 90711 90836 90837 90838	3/1/01 3/1/01 3/3/01 3/3/01 3/10/01 3/10/01 3/16/01 3/16/01 3/17/01 3/17/01 3/17/01	propranolol hydrochloride OxyContin Deltasone methadone hydrochloride OxyContin methadone hydrochloride Deltasone OxyContin warfarin sodium methadone hydrochloride OxyContin	40 mg 80 mg 5 mg 10 mg 80 mg 10 mg 5 mg 80 mg 2.5 mg 10 mg 40 mg	BR BR BR BR JH JH BR BR BR BR BR	90 24 100 100 15 100 100 16 30 100 24
91212 91213 91342 91343 91344 91702 91710 91711	3/22/01 3/22/01 3/24/01 3/24/01 3/24/01 3/29/01 3/30/01 3/30/01	azathioprine OxyContin propranolol hydrochloride methadone hydrochloride OxyContin OxyContin propranolol hydrochloride methadone hydrochloride	50 mg 80 mg 40 mg 10 mg 40 mg 80 mg 40 mg 10 mg	BR BR JH JH JH JH JH JH	15 16 100 100 28 5 100 100
91960 91966 92194 92384 92385 92386 92784 92842 92843 93065 93066	4/2/01 4/2/01 4/5/01 4/7/01 4/7/01 4/7/01 4/13/01 4/13/01 4/13/01 4/17/01 4/17/01	Prozac Pulvules OxyContin OxyContin OxyContin furosemide quinine sulfate methadone hydrochloride OxyContin Prozac Pulvules propranolol hydrochloride OxyContin	20 mg 80 mg 40 mg 80 mg 40 mg 260 mg 10 mg 40 mg 20 mg 40 mg 80 mg	BR BR BR JH JH JH JH BR BR JH JH	10 16 40 20 60 30 100 40 30 100 24
94117 94118 94142 94143 94328 94595 94597 94598 94620 94621	4/20/01 4/20/01 4/21/01 4/21/01 4/24/01 4/27/01 4/27/01 4/27/01 4/28/01 4/28/01	warfarin sodium methadone hydrochloride furosemide OxyContin OxyContin OxyContin quinine sulfate azathioprine methadone hydrochloride OxyContin	2.5 mg 10 mg 40 mg 80 mg 40 mg 80 mg 260 mg 50 mg 10 mg 40 mg	JH JH JH JH DDK KJS KJS KJS JH JH	30 100 60 24 40 28 30 30 100 40
93065 95079 95080 95335 95336 95529 95531 95532 95586 95587 95821 95822 95989 95990 95991 96167 96168 96334 96335 96421 96422 96423 96424 96645	5/4/01 5/4/01 5/4/01 5/8/01 5/8/01 5/11/01 5/11/01 5/11/01 5/12/01 5/12/01 5/15/01 5/15/01 5/17/01 5/17/01 5/17/01 5/21/01 5/21/01 5/23/01 5/23/01 5/24/01 5/24/01 5/24/01 5/24/01 5/29/01	propranolol hydrochloride methadone hydrochloride OxyContin warfarin sodium OxyContin OxyContin warfarin sodium Prozac Pulvules quinine sulfate OxyContin furosemide OxyContin Lonox methadone hydrochloride OxyContin azathioprine OxyContin propranolol hydrochloride OxyContin prednisone furosemide OxyContin methadone hydrochloride OxyContin	40 mg 10 mg 40 mg 2 mg 80 mg 40 mg 2 mg 20 mg 260 mg 80 mg 40 mg 80 mg 2.5/0.025 10 mg 40 mg 50 mg 80 mg 40 mg 40 mg 5 mg 40 mg 80 mg 10 mg 80 mg	JH JH JH DDK DDK KJS KJS KJS BR BR JH JH BR BR BR BR BR BR BR JH JH JH JH JH	100 100 40 30 36 60 30 30 30 38 60 36 60 100 15 15 36 90 60 90 60 15 100 36
96920	6/1/01	OxyContin	40 mg	JH	36
96921	6/1/01	methadone hydrochloride	10 mg	JH	100
96922	6/1/01	Lonox	2.5/0.025	JH	60
96923	6/1/01	azathioprine	50 mg	JH	15
97100	6/4/01	OxyContin	80 mg	BR	20
97309	6/6/01	Amoxicillin	500 mg	BR	28
97310	6/6/01	OxyContin	80 mg	BR	30
97456	6/8/01	furosemide	40 mg	BR	60
97457	6/8/01	methadone hydrochloride	10 mg	BR	100
97582	6/11/01	Prozac Pulvules	90 mg	BR	4
97583	6/11/01	OxyContin	40 mg	BR	60
97740	6/13/01	Levaquin	250 mg	BR	3
97741	6/13/01	OxyContin	80 mg	BR	36
97813	6/14/01	methadone hydrochloride	10 mg	JH	100
98007	6/18/01	quinine sulfate	260 mg	BR	30
98008	6/18/01	OxyContin	40 mg	BR	60
98145	6/20/01	OxyContin	80 mg	BR	36
98236	6/21/01	methadone hydrochloride	10 mg	JH	100
98330	6/23/01	MS Contin	60 mg	BR	60
98331	6/23/01	furosemide	40 mg	BR	60
98448	6/25/01	OxyContin	80 mg	JH	36
98449	6/25/01	azathioprine	50 mg	JH	15
98607	6/27/01	propranolol hydrochloride	40 mg	BR	90
98608	6/27/01	OxyContin	40 mg	BR	36
98609	6/27/01	methadone hydrochloride	10 mg	BR	120
98792	6/30/01	OxyContin	80 mg	JH	36
98793	6/30/01	warfarin sodium	2 mg	JH	30
98885	7/2/01	methadone hydrochloride	10 mg	JH	100
98886	7/2/01	prednisone	5 mg	JH	100
98968	7/3/01	OxyContin	40 mg	JH	50
99143	7/6/01	Prozac Pulvules	20 mg	BR	30
99144	7/6/01	quinine sulfate	260 mg	BR	30
99146	7/6/01	methadone hydrochloride	10 mg	BR	100
99278	7/10/01	methadone hydrochloride	10 mg	BR	100
99569	7/13/01	prednisone	5 mg	JH	100
99570	7/13/01	OxyContin	80 mg	JH	36
99686	7/16/01	OxyContin	40 mg	BR	36
99707	7/17/01	methadone hydrochloride	10 mg	BR	100
99914	7/19/01	furosemide	40 mg	JH	60
99915	7/19/01	methadone hydrochloride	10 mg	JH	120
100103	7/23/01	propranolol hydrochloride	40 mg	JH	90
100104	7/23/01	methadone hydrochloride	10 mg	JH	100
100335	7/27/01	warfarin sodium	2 mg	BR	30
100336	7/27/01	methadone hydrochloride	10 mg	BR	200
100693	8/2/01	Prozac Pulvules	20 mg	BR	7
100694	8/2/01	azathioprine	50 mg	BR	15
100695	8/2/01	methadone hydrochloride	10 mg	BR	200
101039	8/7/01	methadone hydrochloride	10 mg	JH	200
101040	8/7/01	fluoxetine	20 mg	JH	15
101338	8/13/01	methadone hydrochloride	10 mg	BR	200
101339	8/13/01	prednisone	5 mg	BR	100
101808	8/18/01	furosemide	40 mg	MC	30
101809	8/18/01	methadone hydrochloride	10 mg	MC	200
102165	8/23/01	methadone hydrochloride	10 mg	JH	200
102304	8/27/01	OxyContin	80 mg	BR	10
101040	8/31/01	fluoxetine	20 mg	MC	15
102767	8/31/01	methadone hydrochloride	10 mg	MC	200
103215	9/6/01	methadone hydrochloride	10 mg	JH	200
103376	9/8/01	furosemide	40 mg	JH	30
103377	9/8/01	OxyContin	80 mg	JH	20
103446	9/10/01	Propranolol hydrochloride	40 mg	MC	120
103914	9/14/01	methadone hydrochloride	10 mg	MC	200
103915	9/14/01	fluoxetine	20 mg	MC	15
104248	9/19/01	OxyContin	40 mg	MC	48
104249	9/19/01	azathioprine	50 mg	MC	15
104330	9/20/01	methadone hydrochloride	10 mg	JH	200
104646	9/25/01	OxyContin	80 mg	JH	28
104803	9/27/01	methadone hydrochloride	10 mg	JH	200
104804	9/27/01	OxyContin	40 mg	JH	28
104805	9/27/01	fluoxetine	20 mg	JH	30
104806	9/27/01	warfarin sodium	2 mg	JH	30
103446	10/3/01	propranolol hydrochloride	40 mg	MC	120
105194	10/3/01	methadone hydrochloride	10 mg	MC	200
105526	10/9/01	furosemide	40 mg	MC	30
105527	10/9/01	warfarin sodium	2 mg	MC	30
105528	10/9/01	methadone hydrochloride	10 mg	MC	200
105887	10/15/01	fluoxetine	20 mg	BR	30
105888	10/15/01	azathioprine	50 mg	BR	15
105889	10/15/01	methadone hydrochloride	10 mg	BR	200
105890	10/15/01	OxyContin	40 mg	BR	24
106292	10/19/01	methadone hydrochloride	10 mg	BR	200
106771	10/27/01	propranolol hydrochloride	40 mg	MC	100
106772	10/27/01	methadone hydrochloride	10 mg	MC	200
107156	11/2/01	methadone hydrochloride	10 mg	MC	200
107579	11/8/01	fluoxetine	20 mg	JH	30
107580	11/8/01	methadone hydrochloride	10 mg	JH	200
107962	11/14/01	furosemide	40 mg	MC	30
107963	11/14/01	methadone hydrochloride	10 mg	MC	200
108484	11/21/01	methadone hydrochloride	10 mg	MC	200
108485	11/21/01	OxyContin	80 mg	MC	16
108759	11/27/01	methadone hydrochloride	10 mg	JH	200
108760	11/27/01	propranolol hydrochloride	40 mg	JH	100
109116	12/1/01	methadone hydrochloride	10 mg	JH	200
109117	12/1/01	fluoxetine	20 mg	JH	30
109513	12/6/01	OxyContin	80 mg	JH	15
109514	12/6/01	methadone hydrochloride	10 mg	JH	200
109859	12/11/01	methadone hydrochloride	10 mg	JH	200
109860	12/11/01	warfarin sodium	2.5 mg	JH	30
110116	12/14/01	methadone hydrochloride	10 mg	BR	200
110540	12/20/01	methadone hydrochloride	10 mg	JH	200
110752	12/24/01	furosemide	40 mg	BR	30
110753	12/24/01	methadone hydrochloride	10 mg	BR	200
111004	12/28/01	methadone hydrochloride	10 mg	MC	200
111280	1/2/02	fluoxetine	20 mg	JH	15
111281	1/2/02	Dolophine Hydrochloride	10 mg	JH	200
111282	1/2/02	OxyContin	80 mg	JH	10
111280	1/7/02	fluoxetine	20 mg	MC	10
111662	1/7/02	methadone hydrochloride	10 mg	MC	200
108760	1/12/02	propranolol hydrochloride	40 mg	JH	30
112050	1/12/02	methadone hydrochloride	10 mg	JH	200
112372	1/17/02	methadone hydrochloride	10 mg	JH	200
112373	1/17/02	fluoxetine	20 mg	JH	12
112740	1/23/02	methadone hydrochloride	10 mg	MC	200
108760	1/28/02	propranolol hydrochloride	40 mg	MC	20
112993	1/28/02	methadone hydrochloride	10 mg	MC	200
113287	1/31/02	OxyContin	80 mg	JH	40
113734	2/6/02	methadone hydrochloride	10 mg	MC	200
113735	2/6/02	propranolol hydrochloride	40 mg	MC	60
114155	2/12/02	methadone hydrochloride	10 mg	JH	200
112373	2/16/02	fluoxetine	20 mg	MC	60
114436	2/16/02	methadone hydrochloride	10 mg	MC	200
114806	2/21/02	methadone hydrochloride	10 mg	MC	200
114807	2/26/02	propranolol hydrochloride	40 mg	JH	45
115118	2/26/02	methadone hydrochloride	10 mg	JH	200
115360	3/2/02	methadone hydrochloride	10 mg	MC	100
115624	3/6/02	methadone hydrochloride	10 mg	MC	200
112373	3/11/02	fluoxetine	20 mg	MC	60
115969	3/11/02	methadone hydrochloride	10 mg	MC	200
116311	3/16/02	methadone hydrochloride	10 mg	MC	200
114807	3/22/02	propranolol hydrochloride	40 mg	MC	15
116762	3/22/02	methadone hydrochloride	10 mg	MC	200
117031	3/28/02	methadone hydrochloride	10 mg	MC	200
117032	3/28/02	propranolol hydrochloride	40 mg	MC	90
117347	4/3/02	methadone hydrochloride	10 mg	MC	200
117611	4/6/02	methadone hydrochloride	10 mg	JH	200
117612	4/6/02	fluoxetine	20 mg	JH	60

Such conduct is in violation of Rules 4729-5-20 and 4729-5-22 of the Ohio Administrative Code.

Matthew Charles Campbell neither admits nor denies the allegations stated in the amended Notice of Opportunity for Hearing letter however, the Board has evidence sufficient to sustain the allegations and hereby adjudicates the same.

Wherefore, in consideration of the foregoing and mutual promises hereinafter set forth, and in lieu of a formal hearing at this time, Matthew Charles Campbell knowingly and voluntarily agrees with the State Board of Pharmacy to the following:

(A) Matthew Charles Campbell agrees to the imposition of a monetary penalty of Five Hundred Dollars ($500.00) due and owing within 30 days of the effective date of this Agreement. The monetary penalty should be made payable to the “Treasurer, State of Ohio” and mailed with the enclosed form to the State Board of Pharmacy, 77 S. High Street, 17th Floor, Columbus, Ohio 43215-6126.

Matthew Charles Campbell acknowledges that he has had an opportunity to ask questions concerning the terms of this agreement and that all questions asked have been answered in a satisfactory manner. Any action initiated by the Board based on alleged violation of this Agreement shall comply with the Administrative Procedure Act, Chapter 119. of the Ohio Revised Code.

Matthew Charles Campbell waives any and all claims or causes of action he may have against the State of Ohio or the Board, and members, officers, employees, and/or agents of either, arising out of matters which are the subject of this Agreement. Matthew Charles Campbell waives any rights of appeal pursuant to Chapter 119. of the Ohio Revised Code.

This Settlement Agreement shall be considered a public record, as that term is used in Section 149.43 of the Ohio Revised Code, and shall become effective upon the date of the Board President’s signature below.

/s/          Matt Campbell	/d/     5–23–03
Matthew Charles Campbell, Respondent	Date of Signature
/s/          Diane C. Adelman	/d/      6/2/03
Diane C. Adelman, President, Ohio State Board of Pharmacy	Date of Signature
/s/          Sally Ann Steuk	/d/      6–2–03
Sally Ann Steuk, Ohio Assistant Attorney General	Date of Signature

R-2003-181

SETTLEMENT AGREEMENT WITH THE STATE BOARD OF PHARMACY (Docket No. D-021119-032) In The Matter Of: C. JERE HOCHADEL, R.Ph. 36180 Shinning Tree Lane Box 684 Salem, Ohio 44460 (R.Ph. No. 03-1-06992) This Settlement Agreement is entered into by and between C. Jere Hochadel and the Ohio State Board of Pharmacy, a state agency charged with enforcing the Pharmacy Practice Act and Dangerous Drug Distribution Act, Chapter 4729. of the Ohio Revised Code. C. Jere Hochadel voluntarily enters into this Agreement being fully informed of his rights afforded under Chapter 119. of the Ohio Revised Code, including the right to representation by counsel, the right to a formal adjudication hearing on the issues contained herein, and the right to appeal. C. Jere Hochadel acknowledges that by entering into this agreement he has waived his rights under Chapter 119. of the Revised Code. Whereas, the Board is empowered by Section 4729.16 of the Ohio Revised Code to suspend, revoke, place on probation, refuse to grant or renew an identification card or enforce a monetary penalty on the license holder for violation of any of the enumerated grounds therein. Whereas, C. Jere Hochadel is licensed to practice pharmacy in the State of Ohio. Whereas, on or about November 19, 2002, pursuant to Chapter 119. of the Ohio Revised Code, C. Jere Hochadel was notified of the allegations or charges against him, his right to a hearing, his rights in such hearing, and his right to submit contentions in writing. C. Jere Hochadel requested a hearing; it was scheduled and continued. The November 19, 2002, Notice of Opportunity for Hearing, as amended on April 23, 2003, contains the following allegations or charges:

(1)

Records of the Board of Pharmacy indicate that C. Jere Hochadel was originally licensed in the State of Ohio on July 28, 1959, pursuant to examination, and is currently licensed to practice pharmacy in the State of Ohio. Records further reflect during the relevant time periods stated herein, prior to and including December 28, 2001, C. Jere Hochadel was the Responsible Pharmacist at Salem Drug, Inc. pursuant to Sections 4729.27 and 4729.55 of the Ohio Revised Code and Rule 4729-511 of the Ohio Administrative Code.

(2)

C. Jere Hochadel did, from July 22, 2000, to April 6, 2002, continuously failed to perform prospective drug utilization review and patient counseling, to wit: with the patient profile history before him, C. Jere Hochadel and/or pharmacists under his control failed to review the original prescription and/or refill information for over-utilization, incorrect drug dosage and duration of drug treatment, and misuse; and C. Jere Hochadel and/or pharmacists under his control failed to offer patient counseling when dispensing:

Rx #	Date	Drug	Strength	R.Ph.	Qty
74266	7/22/00	OxyContin	40 mg	JH	60
74267	7/22/00	prednisone	10 mg	JH	90
74268	7/22/00	methotrexate	2.5 mg	JH	28
74321	7/24/00	azathioprine	50 mg	JH	30
75112	8/5/00	furosemide	40 mg	BR	60
75113	8/5/00	Coumadin	5 mg	BR	15
75114	8/5/00	methotrexate	2.5 mg	BR	28
75115	8/5/00	OxyContin	40 mg	BR	60
75968	8/19/00	Deltasone	5 mg	BR	120
75969	8/19/00	Coumadin	5 mg	BR	30
75970	8/19/00	azathioprine	50 mg	BR	30
75971	8/19/00	OxyContin	40 mg	BR	60
76588	8/29/00	OxyContin	80 mg	JH	15
76811	9/1/00	furosemide	40 mg	BR	60
76812	9/1/00	methotrexate	2.5 mg	BR	28
76813	9/1/00	Coumadin	2.5 mg	BR	30
76814	9/1/00	Radiacare Gel	4x4 sheet	BR	90
76815	9/1/00	OxyContin	40 mg	BR	90
82872	11/29/00	furosemide	40 mg	BR	60
82873	11/29/00	propranolol hydrochloride	40 mg	BR	90
82874	11/29/00	methotrexate	2.5 mg	BR	16
82875	11/29/00	azathioprine	50 mg	BR	15
82876	11/29/00	OxyContin	40 mg	BR	60
82877	11/29/00	OxyContin	80 mg	BR	6
83699	12/9/00	prednisone	10 mg	BR	30
83700	12/9/00	Radiacare Gel	4x4 sheet	BR	10
83701	12/9/00	OxyContin	80 mg	BR	28
84684	12/22/00	propranolol hydrochloride	40 mg	BR	90
84685	12/22/00	Deltasone	5 mg	BR	60
84686	12/22/00	furosemide	40 mg	BR	60
84687	12/22/00	OxyContin	80 mg	BR	12
84688	12/22/00	OxyContin	40 mg	BR	60
86640	1/20/01	propranolol hydrochloride	40 mg	BR	90
86641	1/20/01	furosemide	40 mg	BR	30
86642	1/20/01	OxyContin	80 mg	BR	20
87114	1/27/01	azathioprine	50 mg	JH	15
87115	1/27/01	OxyContin	40 mg	JH	30
87512	2/1/01	OxyContin	80 mg	JH	5
87520	2/2/01	warfarin sodium	2.5 mg	JH	30
87521	2/2/01	methotrexate	2.5 mg	JH	28
87522	2/2/01	quinine sulfate	260 mg	JH	30
87643	2/3/01	methadone hydrochloride	10 mg	BR	100
88196	2/10/01	propranolol hydrochloride	40 mg	JH	90
88197	2/10/01	OxyContin	80 mg	JH	15
88507	2/14/01	OxyContin	40 mg	JH	30
88508	2/14/01	azathioprine	50 mg	JH	15
88741	2/16/01	Prozac Pulvules	20 mg	BR	30
88742	2/16/01	Radiacare Gel	4x4 sheet	BR	90
88743	2/16/01	methadone hydrochloride	10 mg	BR	100
88744	2/16/01	OxyContin	80 mg	BR	15
89128	2/22/01	furosemide	40 mg	BR	30
89129	2/22/01	OxyContin	80 mg	BR	24
89625	3/1/01	propranolol hydrochloride	40 mg	BR	90
89626	3/1/01	OxyContin	80 mg	BR	24
89836	3/3/01	Deltasone	5 mg	BR	100
89837	3/3/01	methadone hydrochloride	10 mg	BR	100
90331	3/10/01	OxyContin	80 mg	JH	15
90332	3/10/01	methadone hydrochloride	10 mg	JH	100
90710	3/16/01	Deltasone	5 mg	BR	100
90711	3/16/01	OxyContin	80 mg	BR	16
90836	3/17/01	warfarin sodium	2.5 mg	BR	30
90837	3/17/01	methadone hydrochloride	10 mg	BR	100
90838	3/17/01	OxyContin	40 mg	BR	24
91212	3/22/01	azathioprine	50 mg	BR	15
91213	3/22/01	OxyContin	80 mg	BR	16
91342	3/24/01	propranolol hydrochloride	40 mg	JH	100
91343	3/24/01	methadone hydrochloride	10 mg	JH	100
91344	3/24/01	OxyContin	40 mg	JH	28
91702	3/29/01	OxyContin	80 mg	JH	5
91710	3/30/01	propranolol hydrochloride	40 mg	JH	100
91711	3/30/01	methadone hydrochloride	10 mg	JH	100
91960	4/2/01	Prozac Pulvules	20 mg	BR	10
91966	4/2/01	OxyContin	80 mg	BR	16
92194	4/5/01	OxyContin	40 mg	BR	40
92384	4/7/01	OxyContin	80 mg	JH	20
92385	4/7/01	furosemide	40 mg	JH	60
92386	4/7/01	quinine sulfate	260 mg	JH	30
92784	4/13/01	methadone hydrochloride	10 mg	JH	100
92842	4/13/01	OxyContin	40 mg	BR	40
92843	4/13/01	Prozac Pulvules	20 mg	BR	30
93065	4/17/01	propranolol hydrochloride	40 mg	JH	100
93066	4/17/01	OxyContin	80 mg	JH	24
94117	4/20/01	warfarin sodium	2.5 mg	JH	30
94118	4/20/01	methadone hydrochloride	10 mg	JH	100
94142	4/21/01	furosemide	40 mg	JH	60
94143	4/21/01	OxyContin	80 mg	JH	24
94328	4/24/01	OxyContin	40 mg	DDK	40
94595	4/27/01	OxyContin	80 mg	KJS	28
94597	4/27/01	quinine sulfate	260 mg	KJS	30
94598	4/27/01	azathioprine	50 mg	KJS	30
94620	4/28/01	methadone hydrochloride	10 mg	JH	100
94621	4/28/01	OxyContin	40 mg	JH	40
93065	5/4/01	propranolol hydrochloride	40 mg	JH	100
95079	5/4/01	methadone hydrochloride	10 mg	JH	100
95080	5/4/01	OxyContin	40 mg	JH	40
95335	5/8/01	warfarin sodium	2 mg	DDK	30
95336	5/8/01	OxyContin	80 mg	DDK	36
95529	5/11/01	OxyContin	40 mg	KJS	60
95531	5/11/01	warfarin sodium	2 mg	KJS	30
95532	5/11/01	Prozac Pulvules	20 mg	KJS	30
95586	5/12/01	quinine sulfate	260 mg	BR	30
95587	5/12/01	OxyContin	80 mg	BR	38
95821	5/15/01	furosemide	40 mg	JH	60
95822	5/15/01	OxyContin	80 mg	JH	36
95989	5/17/01	Lonox	2.5/0.025	BR	60
95990	5/17/01	methadone hydrochloride	10 mg	BR	100
95991	5/17/01	OxyContin	40 mg	BR	15
96167	5/21/01	azathioprine	50 mg	BR	15
96168	5/21/01	OxyContin	80 mg	BR	36
96334	5/23/01	propranolol hydrochloride	40 mg	BR	90
96335	5/23/01	OxyContin	40 mg	BR	60
96421	5/24/01	prednisone	5 mg	JH	90
96422	5/24/01	furosemide	40 mg	JH	60
96423	5/24/01	OxyContin	80 mg	JH	15
96424	5/24/01	methadone hydrochloride	10 mg	JH	100
96645	5/29/01	OxyContin	80 mg	JH	36
96920	6/1/01	OxyContin	40 mg	JH	36
96921	6/1/01	methadone hydrochloride	10 mg	JH	100
96922	6/1/01	Lonox	2.5/0.025	JH	60
96923	6/1/01	azathioprine	50 mg	JH	15
97100	6/4/01	OxyContin	80 mg	BR	20
97309	6/6/01	Amoxicillin	500 mg	BR	28
97310	6/6/01	OxyContin	80 mg	BR	30
97456	6/8/01	furosemide	40 mg	BR	60
97457	6/8/01	methadone hydrochloride	10 mg	BR	100
97582	6/11/01	Prozac Pulvules	90 mg	BR	4
97583	6/11/01	OxyContin	40 mg	BR	60
97740	6/13/01	Levaquin	250 mg	BR	3
97741	6/13/01	OxyContin	80 mg	BR	36
97813	6/14/01	methadone hydrochloride	10 mg	JH	100
98007	6/18/01	quinine sulfate	260 mg	BR	30
98008	6/18/01	OxyContin	40 mg	BR	60
98145	6/20/01	OxyContin	80 mg	BR	36
98236	6/21/01	methadone hydrochloride	10 mg	JH	100
98330	6/23/01	MS Contin	60 mg	BR	60
98331	6/23/01	furosemide	40 mg	BR	60
98448	6/25/01	OxyContin	80 mg	JH	36
98449	6/25/01	azathioprine	50 mg	JH	15
98607	6/27/01	propranolol hydrochloride	40 mg	BR	90
98608	6/27/01	OxyContin	40 mg	BR	36
98609	6/27/01	methadone hydrochloride	10 mg	BR	120
98792	6/30/01	OxyContin	80 mg	JH	36
98793	6/30/01	warfarin sodium	2 mg	JH	30
98885	7/2/01	methadone hydrochloride	10 mg	JH	100
98886	7/2/01	prednisone	5 mg	JH	100
98968	7/3/01	OxyContin	40 mg	JH	50
99143	7/6/01	Prozac Pulvules	20 mg	BR	30
99144	7/6/01	quinine sulfate	260 mg	BR	30
99146	7/6/01	methadone hydrochloride	10 mg	BR	100
99278	7/10/01	methadone hydrochloride	10 mg	BR	100
99569	7/13/01	prednisone	5 mg	JH	100
99570	7/13/01	OxyContin	80 mg	JH	36
99686	7/16/01	OxyContin	40 mg	BR	36
99707	7/17/01	methadone hydrochloride	10 mg	BR	100
99914	7/19/01	furosemide	40 mg	JH	60
99915	7/19/01	methadone hydrochloride	10 mg	JH	120
100103	7/23/01	propranolol hydrochloride	40 mg	JH	90
100104	7/23/01	methadone hydrochloride	10 mg	JH	100
100335	7/27/01	warfarin sodium	2 mg	BR	30
100336	7/27/01	methadone hydrochloride	10 mg	BR	200
100693	8/2/01	Prozac Pulvules	20 mg	BR	7
100694	8/2/01	azathioprine	50 mg	BR	15
100695	8/2/01	methadone hydrochloride	10 mg	BR	200
101039	8/7/01	methadone hydrochloride	10 mg	JH	200
101040	8/7/01	fluoxetine	20 mg	JH	15
101338	8/13/01	methadone hydrochloride	10 mg	BR	200
101339	8/13/01	prednisone	5 mg	BR	100
101808	8/18/01	furosemide	40 mg	MC	30
101809	8/18/01	methadone hydrochloride	10 mg	MC	200
102165	8/23/01	methadone hydrochloride	10 mg	JH	200
102304	8/27/01	OxyContin	80 mg	BR	10
101040	8/31/01	fluoxetine	20 mg	MC	15
102767	8/31/01	methadone hydrochloride	10 mg	MC	200
103215	9/6/01	methadone hydrochloride	10 mg	JH	200
103376	9/8/01	furosemide	40 mg	JH	30
103377	9/8/01	OxyContin	80 mg	JH	20
103446	9/10/01	Propranolol hydrochloride	40 mg	MC	120
103914	9/14/01	methadone hydrochloride	10 mg	MC	200
103915	9/14/01	fluoxetine	20 mg	MC	15
104248	9/19/01	OxyContin	40 mg	MC	48
104249	9/19/01	azathioprine	50 mg	MC	15
104330	9/20/01	methadone hydrochloride	10 mg	JH	200
104646	9/25/01	OxyContin	80 mg	JH	28
104803	9/27/01	methadone hydrochloride	10 mg	JH	200
104804	9/27/01	OxyContin	40 mg	JH	28
104805	9/27/01	fluoxetine	20 mg	JH	30
104806	9/27/01	warfarin sodium	2 mg	JH	30
103446	10/3/01	propranolol hydrochloride	40 mg	MC	120
105194	10/3/01	methadone hydrochloride	10 mg	MC	200
105526	10/9/01	furosemide	40 mg	MC	30
105527	10/9/01	warfarin sodium	2 mg	MC	30
105528	10/9/01	methadone hydrochloride	10 mg	MC	200
105887	10/15/01	fluoxetine	20 mg	BR	30
105888	10/15/01	azathioprine	50 mg	BR	15
105889	10/15/01	methadone hydrochloride	10 mg	BR	200
105890	10/15/01	OxyContin	40 mg	BR	24
106292	10/19/01	methadone hydrochloride	10 mg	BR	200
106771	10/27/01	propranolol hydrochloride	40 mg	MC	100
106772	10/27/01	methadone hydrochloride	10 mg	MC	200
107156	11/2/01	methadone hydrochloride	10 mg	MC	200
107579	11/8/01	fluoxetine	20 mg	JH	30
107580	11/8/01	methadone hydrochloride	10 mg	JH	200
107962	11/14/01	furosemide	40 mg	MC	30
107963	11/14/01	methadone hydrochloride	10 mg	MC	200
108484	11/21/01	methadone hydrochloride	10 mg	MC	200
108485	11/21/01	OxyContin	80 mg	MC	16
108759	11/27/01	methadone hydrochloride	10 mg	JH	200
108760	11/27/01	propranolol hydrochloride	40 mg	JH	100
109116	12/1/01	methadone hydrochloride	10 mg	JH	200
109117	12/1/01	fluoxetine	20 mg	JH	30
109513	12/6/01	OxyContin	80 mg	JH	15
109514	12/6/01	methadone hydrochloride	10 mg	JH	200
109859	12/11/01	methadone hydrochloride	10 mg	JH	200
109860	12/11/01	warfarin sodium	2.5 mg	JH	30
110116	12/14/01	methadone hydrochloride	10 mg	BR	200
110540	12/20/01	methadone hydrochloride	10 mg	JH	200
110752	12/24/01	furosemide	40 mg	BR	30
110753	12/24/01	methadone hydrochloride	10 mg	BR	200
111004	12/28/01	methadone hydrochloride	10 mg	MC	200
111280	1/2/02	fluoxetine	20 mg	JH	15
111281	1/2/02	Dolophine Hydrochloride	10 mg	JH	200
111282	1/2/02	OxyContin	80 mg	JH	10
111280	1/7/02	fluoxetine	20 mg	MC	10
111662	1/7/02	methadone hydrochloride	10 mg	MC	200
108760	1/12/02	propranolol hydrochloride	40 mg	JH	30
112050	1/12/02	methadone hydrochloride	10 mg	JH	200
112372	1/17/02	methadone hydrochloride	10 mg	JH	200
112373	1/17/02	fluoxetine	20 mg	JH	12
112740	1/23/02	methadone hydrochloride	10 mg	MC	200
108760	1/28/02	propranolol hydrochloride	40 mg	MC	20
112993	1/28/02	methadone hydrochloride	10 mg	MC	200
113287	1/31/02	OxyContin	80 mg	JH	40
113734	2/6/02	methadone hydrochloride	10 mg	MC	200
113735	2/6/02	propranolol hydrochloride	40 mg	MC	60
114155	2/12/02	methadone hydrochloride	10 mg	JH	200
112373	2/16/02	fluoxetine	20 mg	MC	60
114436	2/16/02	methadone hydrochloride	10 mg	MC	200
114806	2/21/02	methadone hydrochloride	10 mg	MC	200
114807	2/26/02	propranolol hydrochloride	40 mg	JH	45
115118	2/26/02	methadone hydrochloride	10 mg	JH	200
115360	3/2/02	methadone hydrochloride	10 mg	MC	100
115624	3/6/02	methadone hydrochloride	10 mg	MC	200
112373	3/11/02	fluoxetine	20 mg	MC	60
115969	3/11/02	methadone hydrochloride	10 mg	MC	200
116311	3/16/02	methadone hydrochloride	10 mg	MC	200
114807	3/22/02	propranolol hydrochloride	40 mg	MC	15
116762	3/22/02	methadone hydrochloride	10 mg	MC	200
117031	3/28/02	methadone hydrochloride	10 mg	MC	200
117032	3/28/02	propranolol hydrochloride	40 mg	MC	90
117347	4/3/02	methadone hydrochloride	10 mg	MC	200
117611	4/6/02	methadone hydrochloride	10 mg	JH	200
117612	4/6/02	fluoxetine	20 mg	JH	60

Such conduct is in violation of Rules 4729-5-20 and 4729-5-22 of the Ohio Administrative Code.

C. Jere Hochadel neither admits nor denies the allegations stated in the amended Notice of Opportunity for Hearing letter however, the Board has evidence sufficient to sustain the allegations and hereby adjudicates the same.

Wherefore, in consideration of the foregoing and mutual promises hereinafter set forth, and in lieu of a formal hearing at this time, C. Jere Hochadel knowingly and voluntarily agrees with the State Board of Pharmacy to the following:

(A) C. Jere Hochadel agrees to the imposition of a monetary penalty of Five Hundred Dollars ($500.00) due and owing within 30 days of the effective date of this Agreement. The monetary penalty should be made payable to the “Treasurer, State of Ohio” and mailed with the enclosed form to the State Board of Pharmacy, 77 S. High Street, 17th Floor, Columbus, Ohio 43215-6126.

C. Jere Hochadel acknowledges that he has had an opportunity to ask questions concerning the terms of this agreement and that all questions asked have been answered in a satisfactory manner. Any action initiated by the Board based on alleged violation of this Agreement shall comply with the Administrative Procedure Act, Chapter 119. of the Ohio Revised Code.

C. Jere Hochadel waives any and all claims or causes of action he may have against the State of Ohio or the Board, and members, officers, employees, and/or agents of either, arising out of matters which are the subject of this Agreement. C. Jere Hochadel waives any rights of appeal pursuant to Chapter 119. of the Ohio Revised Code.

This Settlement Agreement shall be considered a public record, as that term is used in Section 149.43 of the Ohio Revised Code, and shall become effective upon the date of the Board President’s signature below.

/s/          C. Jere Hochadel RPh	/d/     5/23/03
C. Jere Hochadel, Respondent	Date of Signature
/s/          Diane C. Adelman	/d/      6/2/03
Diane C. Adelman, President, Ohio State Board of Pharmacy	Date of Signature
/s/          Sally Ann Steuk	/d/      6–2–03
Sally Ann Steuk, Ohio Assistant Attorney General	Date of Signature

R-2003-182

SETTLEMENT AGREEMENT WITH THE STATE BOARD OF PHARMACY (Docket No. D-021119-034) In The Matter Of: A. WILLIAM RICHERT, R.Ph. 12 Overlook Drive McCormick, South Carolina 29835 (R.Ph. No. 03-3-07544) This Settlement Agreement is entered into by and between A. William Richert and the Ohio State Board of Pharmacy, a state agency charged with enforcing the Pharmacy Practice Act and Dangerous Drug Distribution Act, Chapter 4729. of the Ohio Revised Code. A. William Richert voluntarily enters into this Agreement being fully informed of his rights afforded under Chapter 119. of the Ohio Revised Code, including the right to representation by counsel, the right to a formal adjudication hearing on the issues contained herein, and the right to appeal. A. William Richert acknowledges that by entering into this agreement he has waived his rights under Chapter 119. of the Revised Code. Whereas, the Board is empowered by Section 4729.16 of the Ohio Revised Code to suspend, revoke, place on probation, refuse to grant or renew an identification card or enforce a monetary penalty on the license holder for violation of any of the enumerated grounds therein. Whereas, A. William Richert is licensed to practice pharmacy in the State of Ohio. Whereas, on or about November 19, 2002, pursuant to Chapter 119. of the Ohio Revised Code, A. William Richert was notified of the allegations or charges against him, his right to a hearing, his rights in such hearing, and his right to submit contentions in writing. A. William Richert requested a hearing; it was scheduled and continued. The November 19, 2002, Notice of Opportunity for Hearing, as amended on April 23, 2003, contains the following allegations or charges:

(1)

Records of the Board of Pharmacy indicate that A. William Richert was originally licensed in the State of Ohio on August 28, 1961, pursuant to examination, and is currently licensed to practice pharmacy in the State of Ohio.

(2)

A. William Richert did, from August 5, 2000, to December 24, 2001, continuously failed to perform prospective drug utilization review and patient counseling, to wit: with the patient profile history before him, A. William Richert failed to review the original prescription and/or refill information for over-utilization, incorrect drug dosage and duration of drug treatment, and misuse; and he failed to offer patient counseling when dispensing:

Rx #	Date	Drug	Strength	R.Ph.	Qty
74266	7/22/00	OxyContin	40 mg	JH	60
74267	7/22/00	prednisone	10 mg	JH	90
74268	7/22/00	methotrexate	2.5 mg	JH	28
74321	7/24/00	azathioprine	50 mg	JH	30
75112	8/5/00	furosemide	40 mg	BR	60
75113	8/5/00	Coumadin	5 mg	BR	15
75114	8/5/00	methotrexate	2.5 mg	BR	28
75115	8/5/00	OxyContin	40 mg	BR	60
75968	8/19/00	Deltasone	5 mg	BR	120
75969	8/19/00	Coumadin	5 mg	BR	30
75970	8/19/00	azathioprine	50 mg	BR	30
75971	8/19/00	OxyContin	40 mg	BR	60
76588	8/29/00	OxyContin	80 mg	JH	15
76811	9/1/00	furosemide	40 mg	BR	60
76812	9/1/00	methotrexate	2.5 mg	BR	28
76813	9/1/00	Coumadin	2.5 mg	BR	30
76814	9/1/00	Radiacare Gel	4x4 sheet	BR	90
76815	9/1/00	OxyContin	40 mg	BR	90
82872	11/29/00	furosemide	40 mg	BR	60
82873	11/29/00	propranolol hydrochloride	40 mg	BR	90
82874	11/29/00	methotrexate	2.5 mg	BR	16
82875	11/29/00	azathioprine	50 mg	BR	15
82876	11/29/00	OxyContin	40 mg	BR	60
82877	11/29/00	OxyContin	80 mg	BR	6
83699	12/9/00	prednisone	10 mg	BR	30
83700	12/9/00	Radiacare Gel	4x4 sheet	BR	10
83701	12/9/00	OxyContin	80 mg	BR	28
84684	12/22/00	propranolol hydrochloride	40 mg	BR	90
84685	12/22/00	Deltasone	5 mg	BR	60
84686	12/22/00	furosemide	40 mg	BR	60
84687	12/22/00	OxyContin	80 mg	BR	12
84688	12/22/00	OxyContin	40 mg	BR	60
86640	1/20/01	propranolol hydrochloride	40 mg	BR	90
86641	1/20/01	furosemide	40 mg	BR	30
86642	1/20/01	OxyContin	80 mg	BR	20
87114	1/27/01	azathioprine	50 mg	JH	15
87115	1/27/01	OxyContin	40 mg	JH	30
87512	2/1/01	OxyContin	80 mg	JH	5
87520	2/2/01	warfarin sodium	2.5 mg	JH	30
87521	2/2/01	methotrexate	2.5 mg	JH	28
87522	2/2/01	quinine sulfate	260 mg	JH	30
87643	2/3/01	methadone hydrochloride	10 mg	BR	100
88196	2/10/01	propranolol hydrochloride	40 mg	JH	90
88197	2/10/01	OxyContin	80 mg	JH	15
88507	2/14/01	OxyContin	40 mg	JH	30
88508	2/14/01	azathioprine	50 mg	JH	15
88741	2/16/01	Prozac Pulvules	20 mg	BR	30
88742	2/16/01	Radiacare Gel	4x4 sheet	BR	90
88743	2/16/01	methadone hydrochloride	10 mg	BR	100
88744	2/16/01	OxyContin	80 mg	BR	15
89128	2/22/01	furosemide	40 mg	BR	30
89129	2/22/01	OxyContin	80 mg	BR	24
89625	3/1/01	propranolol hydrochloride	40 mg	BR	90
89626	3/1/01	OxyContin	80 mg	BR	24
89836	3/3/01	Deltasone	5 mg	BR	100
89837	3/3/01	methadone hydrochloride	10 mg	BR	100
90331	3/10/01	OxyContin	80 mg	JH	15
90332	3/10/01	methadone hydrochloride	10 mg	JH	100
90710	3/16/01	Deltasone	5 mg	BR	100
90711	3/16/01	OxyContin	80 mg	BR	16
90836	3/17/01	warfarin sodium	2.5 mg	BR	30
90837	3/17/01	methadone hydrochloride	10 mg	BR	100
90838	3/17/01	OxyContin	40 mg	BR	24
91212	3/22/01	azathioprine	50 mg	BR	15
91213	3/22/01	OxyContin	80 mg	BR	16
91342	3/24/01	propranolol hydrochloride	40 mg	JH	100
91343	3/24/01	methadone hydrochloride	10 mg	JH	100
91344	3/24/01	OxyContin	40 mg	JH	28
91702	3/29/01	OxyContin	80 mg	JH	5
91710	3/30/01	propranolol hydrochloride	40 mg	JH	100
91711	3/30/01	methadone hydrochloride	10 mg	JH	100
91960	4/2/01	Prozac Pulvules	20 mg	BR	10
91966	4/2/01	OxyContin	80 mg	BR	16
92194	4/5/01	OxyContin	40 mg	BR	40
92384	4/7/01	OxyContin	80 mg	JH	20
92385	4/7/01	furosemide	40 mg	JH	60
92386	4/7/01	quinine sulfate	260 mg	JH	30
92784	4/13/01	methadone hydrochloride	10 mg	JH	100
92842	4/13/01	OxyContin	40 mg	BR	40
92843	4/13/01	Prozac Pulvules	20 mg	BR	30
93065	4/17/01	propranolol hydrochloride	40 mg	JH	100
93066	4/17/01	OxyContin	80 mg	JH	24
94117	4/20/01	warfarin sodium	2.5 mg	JH	30
94118	4/20/01	methadone hydrochloride	10 mg	JH	100
94142	4/21/01	furosemide	40 mg	JH	60
94143	4/21/01	OxyContin	80 mg	JH	24
94328	4/24/01	OxyContin	40 mg	DDK	40
94595	4/27/01	OxyContin	80 mg	KJS	28
94597	4/27/01	quinine sulfate	260 mg	KJS	30
94598	4/27/01	azathioprine	50 mg	KJS	30
94620	4/28/01	methadone hydrochloride	10 mg	JH	100
94621	4/28/01	OxyContin	40 mg	JH	40
93065	5/4/01	propranolol hydrochloride	40 mg	JH	100
95079	5/4/01	methadone hydrochloride	10 mg	JH	100
95080	5/4/01	OxyContin	40 mg	JH	40
95335	5/8/01	warfarin sodium	2 mg	DDK	30
95336	5/8/01	OxyContin	80 mg	DDK	36
95529	5/11/01	OxyContin	40 mg	KJS	60
95531	5/11/01	warfarin sodium	2 mg	KJS	30
95532	5/11/01	Prozac Pulvules	20 mg	KJS	30
95586	5/12/01	quinine sulfate	260 mg	BR	30
95587	5/12/01	OxyContin	80 mg	BR	38
95821	5/15/01	furosemide	40 mg	JH	60
95822	5/15/01	OxyContin	80 mg	JH	36
95989	5/17/01	Lonox	2.5/0.025	BR	60
95990	5/17/01	methadone hydrochloride	10 mg	BR	100
95991	5/17/01	OxyContin	40 mg	BR	15
96167	5/21/01	azathioprine	50 mg	BR	15
96168	5/21/01	OxyContin	80 mg	BR	36
96334	5/23/01	propranolol hydrochloride	40 mg	BR	90
96335	5/23/01	OxyContin	40 mg	BR	60
96421	5/24/01	prednisone	5 mg	JH	90
96422	5/24/01	furosemide	40 mg	JH	60
96423	5/24/01	OxyContin	80 mg	JH	15
96424	5/24/01	methadone hydrochloride	10 mg	JH	100
96645	5/29/01	OxyContin	80 mg	JH	36
96920	6/1/01	OxyContin	40 mg	JH	36
96921	6/1/01	methadone hydrochloride	10 mg	JH	100
96922	6/1/01	Lonox	2.5/0.025	JH	60
96923	6/1/01	azathioprine	50 mg	JH	15
97100	6/4/01	OxyContin	80 mg	BR	20
97309	6/6/01	Amoxicillin	500 mg	BR	28
97310	6/6/01	OxyContin	80 mg	BR	30
97456	6/8/01	furosemide	40 mg	BR	60
97457	6/8/01	methadone hydrochloride	10 mg	BR	100
97582	6/11/01	Prozac Pulvules	90 mg	BR	4
97583	6/11/01	OxyContin	40 mg	BR	60
97740	6/13/01	Levaquin	250 mg	BR	3
97741	6/13/01	OxyContin	80 mg	BR	36
97813	6/14/01	methadone hydrochloride	10 mg	JH	100
98007	6/18/01	quinine sulfate	260 mg	BR	30
98008	6/18/01	OxyContin	40 mg	BR	60
98145	6/20/01	OxyContin	80 mg	BR	36
98236	6/21/01	methadone hydrochloride	10 mg	JH	100
98330	6/23/01	MS Contin	60 mg	BR	60
98331	6/23/01	furosemide	40 mg	BR	60
98448	6/25/01	OxyContin	80 mg	JH	36
98449	6/25/01	azathioprine	50 mg	JH	15
98607	6/27/01	propranolol hydrochloride	40 mg	BR	90
98608	6/27/01	OxyContin	40 mg	BR	36
98609	6/27/01	methadone hydrochloride	10 mg	BR	120
98792	6/30/01	OxyContin	80 mg	JH	36
98793	6/30/01	warfarin sodium	2 mg	JH	30
98885	7/2/01	methadone hydrochloride	10 mg	JH	100
98886	7/2/01	prednisone	5 mg	JH	100
98968	7/3/01	OxyContin	40 mg	JH	50
99143	7/6/01	Prozac Pulvules	20 mg	BR	30
99144	7/6/01	quinine sulfate	260 mg	BR	30
99146	7/6/01	methadone hydrochloride	10 mg	BR	100
99278	7/10/01	methadone hydrochloride	10 mg	BR	100
99569	7/13/01	prednisone	5 mg	JH	100
99570	7/13/01	OxyContin	80 mg	JH	36
99686	7/16/01	OxyContin	40 mg	BR	36
99707	7/17/01	methadone hydrochloride	10 mg	BR	100
99914	7/19/01	furosemide	40 mg	JH	60
99915	7/19/01	methadone hydrochloride	10 mg	JH	120
100103	7/23/01	propranolol hydrochloride	40 mg	JH	90
100104	7/23/01	methadone hydrochloride	10 mg	JH	100
100335	7/27/01	warfarin sodium	2 mg	BR	30
100336	7/27/01	methadone hydrochloride	10 mg	BR	200
100693	8/2/01	Prozac Pulvules	20 mg	BR	7
100694	8/2/01	azathioprine	50 mg	BR	15
100695	8/2/01	methadone hydrochloride	10 mg	BR	200
101039	8/7/01	methadone hydrochloride	10 mg	JH	200
101040	8/7/01	fluoxetine	20 mg	JH	15
101338	8/13/01	methadone hydrochloride	10 mg	BR	200
101339	8/13/01	prednisone	5 mg	BR	100
101808	8/18/01	furosemide	40 mg	MC	30
101809	8/18/01	methadone hydrochloride	10 mg	MC	200
102165	8/23/01	methadone hydrochloride	10 mg	JH	200
102304	8/27/01	OxyContin	80 mg	BR	10
101040	8/31/01	fluoxetine	20 mg	MC	15
102767	8/31/01	methadone hydrochloride	10 mg	MC	200
103215	9/6/01	methadone hydrochloride	10 mg	JH	200
103376	9/8/01	furosemide	40 mg	JH	30
103377	9/8/01	OxyContin	80 mg	JH	20
103446	9/10/01	Propranolol hydrochloride	40 mg	MC	120
103914	9/14/01	methadone hydrochloride	10 mg	MC	200
103915	9/14/01	fluoxetine	20 mg	MC	15
104248	9/19/01	OxyContin	40 mg	MC	48
104249	9/19/01	azathioprine	50 mg	MC	15
104330	9/20/01	methadone hydrochloride	10 mg	JH	200
104646	9/25/01	OxyContin	80 mg	JH	28
104803	9/27/01	methadone hydrochloride	10 mg	JH	200
104804	9/27/01	OxyContin	40 mg	JH	28
104805	9/27/01	fluoxetine	20 mg	JH	30
104806	9/27/01	warfarin sodium	2 mg	JH	30
103446	10/3/01	propranolol hydrochloride	40 mg	MC	120
105194	10/3/01	methadone hydrochloride	10 mg	MC	200
105526	10/9/01	furosemide	40 mg	MC	30
105527	10/9/01	warfarin sodium	2 mg	MC	30
105528	10/9/01	methadone hydrochloride	10 mg	MC	200
105887	10/15/01	fluoxetine	20 mg	BR	30
105888	10/15/01	azathioprine	50 mg	BR	15
105889	10/15/01	methadone hydrochloride	10 mg	BR	200
105890	10/15/01	OxyContin	40 mg	BR	24
106292	10/19/01	methadone hydrochloride	10 mg	BR	200
106771	10/27/01	propranolol hydrochloride	40 mg	MC	100
106772	10/27/01	methadone hydrochloride	10 mg	MC	200
107156	11/2/01	methadone hydrochloride	10 mg	MC	200
107579	11/8/01	fluoxetine	20 mg	JH	30
107580	11/8/01	methadone hydrochloride	10 mg	JH	200
107962	11/14/01	furosemide	40 mg	MC	30
107963	11/14/01	methadone hydrochloride	10 mg	MC	200
108484	11/21/01	methadone hydrochloride	10 mg	MC	200
108485	11/21/01	OxyContin	80 mg	MC	16
108759	11/27/01	methadone hydrochloride	10 mg	JH	200
108760	11/27/01	propranolol hydrochloride	40 mg	JH	100
109116	12/1/01	methadone hydrochloride	10 mg	JH	200
109117	12/1/01	fluoxetine	20 mg	JH	30
109513	12/6/01	OxyContin	80 mg	JH	15
109514	12/6/01	methadone hydrochloride	10 mg	JH	200
109859	12/11/01	methadone hydrochloride	10 mg	JH	200
109860	12/11/01	warfarin sodium	2.5 mg	JH	30
110116	12/14/01	methadone hydrochloride	10 mg	BR	200
110540	12/20/01	methadone hydrochloride	10 mg	JH	200
110752	12/24/01	furosemide	40 mg	BR	30
110753	12/24/01	methadone hydrochloride	10 mg	BR	200
111004	12/28/01	methadone hydrochloride	10 mg	MC	200
111280	1/2/02	fluoxetine	20 mg	JH	15
111281	1/2/02	Dolophine Hydrochloride	10 mg	JH	200
111282	1/2/02	OxyContin	80 mg	JH	10
111280	1/7/02	fluoxetine	20 mg	MC	10
111662	1/7/02	methadone hydrochloride	10 mg	MC	200
108760	1/12/02	propranolol hydrochloride	40 mg	JH	30
112050	1/12/02	methadone hydrochloride	10 mg	JH	200
112372	1/17/02	methadone hydrochloride	10 mg	JH	200
112373	1/17/02	fluoxetine	20 mg	JH	12
112740	1/23/02	methadone hydrochloride	10 mg	MC	200
108760	1/28/02	propranolol hydrochloride	40 mg	MC	20
112993	1/28/02	methadone hydrochloride	10 mg	MC	200
113287	1/31/02	OxyContin	80 mg	JH	40
113734	2/6/02	methadone hydrochloride	10 mg	MC	200
113735	2/6/02	propranolol hydrochloride	40 mg	MC	60
114155	2/12/02	methadone hydrochloride	10 mg	JH	200
112373	2/16/02	fluoxetine	20 mg	MC	60
114436	2/16/02	methadone hydrochloride	10 mg	MC	200
114806	2/21/02	methadone hydrochloride	10 mg	MC	200
114807	2/26/02	propranolol hydrochloride	40 mg	JH	45
115118	2/26/02	methadone hydrochloride	10 mg	JH	200
115360	3/2/02	methadone hydrochloride	10 mg	MC	100
115624	3/6/02	methadone hydrochloride	10 mg	MC	200
112373	3/11/02	fluoxetine	20 mg	MC	60
115969	3/11/02	methadone hydrochloride	10 mg	MC	200
116311	3/16/02	methadone hydrochloride	10 mg	MC	200
114807	3/22/02	propranolol hydrochloride	40 mg	MC	15
116762	3/22/02	methadone hydrochloride	10 mg	MC	200
117031	3/28/02	methadone hydrochloride	10 mg	MC	200
117032	3/28/02	propranolol hydrochloride	40 mg	MC	90
117347	4/3/02	methadone hydrochloride	10 mg	MC	200
117611	4/6/02	methadone hydrochloride	10 mg	JH	200
117612	4/6/02	fluoxetine	20 mg	JH	60

Such conduct is in violation of Rules 4729-5-20 and 4729-5-22 of the Ohio Administrative Code.

A. William Richert neither admits nor denies the allegations stated in the amended Notice of Opportunity for Hearing letter however, the Board has evidence sufficient to sustain the allegations and hereby adjudicates the same.

Wherefore, in consideration of the foregoing and mutual promises hereinafter set forth, and in lieu of a formal hearing at this time, A. William Richert knowingly and voluntarily agrees with the State Board of Pharmacy to the following:

(A) A. William Richert agrees to the imposition of a monetary penalty of Five Hundred Dollars ($500.00) due and owing within 30 days of the effective date of this Agreement. The monetary penalty should be made payable to the “Treasurer, State of Ohio” and mailed with the enclosed form to the State Board of Pharmacy, 77 S. High Street, 17th Floor, Columbus, Ohio 43215-6126.

A. William Richert acknowledges that he has had an opportunity to ask questions concerning the terms of this agreement and that all questions asked have been answered in a satisfactory manner. Any action initiated by the Board based on alleged violation of this Agreement shall comply with the Administrative Procedure Act, Chapter 119. of the Ohio Revised Code.

A. William Richert waives any and all claims or causes of action he may have against the State of Ohio or the Board, and members, officers, employees, and/or agents of either, arising out of matters which are the subject of this Agreement. A. William Richert waives any rights of appeal pursuant to Chapter 119. of the Ohio Revised Code.

This Settlement Agreement shall be considered a public record, as that term is used in Section 149.43 of the Ohio Revised Code, and shall become effective upon the date of the Board President’s signature below.

/s/          A. William Richert, Respondent	/d/   5–27–2003
A. William Richert, Respondent	Date of Signature
/s/          Diane C. Adelman	/d/      6/2/03
Diane C. Adelman, President, Ohio State Board of Pharmacy	Date of Signature
/s/          Sally Ann Steuk	/d/      6–2–03
Sally Ann Steuk, Ohio Assistant Attorney General	Date of Signature

R-2003-183

SETTLEMENT AGREEMENT WITH THE STATE BOARD OF PHARMACY (Docket No. D-021119-033 In The Matter Of: KEVIN JOHN SNYDER, R.Ph. 307 West Lincoln Way Lisbon, Ohio 44432 (R.Ph. No. 03-2-13781) This Settlement Agreement is entered into by and between Kevin John Snyder and the Ohio State Board of Pharmacy, a state agency charged with enforcing the Pharmacy Practice Act and Dangerous Drug Distribution Act, Chapter 4729. of the Ohio Revised Code. Kevin John Snyder voluntarily enters into this Agreement being fully informed of his rights afforded under Chapter 119. of the Ohio Revised Code, including the right to representation by counsel, the right to a formal adjudication hearing on the issues contained herein, and the right to appeal. Kevin John Snyder acknowledges that by entering into this agreement he has waived his rights under Chapter 119. of the Revised Code. Whereas, the Board is empowered by Section 4729.16 of the Ohio Revised Code to suspend, revoke, place on probation, refuse to grant or renew an identification card or enforce a monetary penalty on the license holder for violation of any of the enumerated grounds therein. Whereas, Kevin John Snyder is licensed to practice pharmacy in the State of Ohio. Whereas, on or about November 19, 2002, pursuant to Chapter 119. of the Ohio Revised Code, Kevin John Snyder was notified of the allegations or charges against him, his right to a hearing, his rights in such hearing, and his right to submit contentions in writing. Kevin John Snyder requested a hearing; it was scheduled and continued. The November 19, 2002 Notice of Opportunity for Hearing, as amended on April 23, 2003, contains the following allegations or charges:

(1) Records of the Board of Pharmacy indicate that Kevin John Snyder was originally licensed in the State of Ohio on December 2, 1980, pursuant to examination, and is currently licensed to practice pharmacy in the State of Ohio. (2) Kevin John Snyder did, from March 1, 2001, to May 11, 2001, continuously failed to perform prospective drug utilization review and patient counseling, to wit: with the patient profile history before him, Kevin John Snyder failed to review the original prescription and/or refill information for over-utilization, incorrect drug dosage and duration of drug treatment, and misuse; and he failed to offer patient counseling when dispensing:

Rx #	Date	Drug	Strength	R.Ph.	Qty
74266	7/22/00	OxyContin	40 mg	JH	60
74267	7/22/00	prednisone	10 mg	JH	90
74268	7/22/00	methotrexate	2.5 mg	JH	28
74321	7/24/00	azathioprine	50 mg	JH	30
75112	8/5/00	furosemide	40 mg	BR	60
75113	8/5/00	Coumadin	5 mg	BR	15
75114	8/5/00	methotrexate	2.5 mg	BR	28
75115	8/5/00	OxyContin	40 mg	BR	60
75968	8/19/00	Deltasone	5 mg	BR	120
75969	8/19/00	Coumadin	5 mg	BR	30
75970	8/19/00	azathioprine	50 mg	BR	30
75971	8/19/00	OxyContin	40 mg	BR	60
76588	8/29/00	OxyContin	80 mg	JH	15
76811	9/1/00	furosemide	40 mg	BR	60
76812	9/1/00	methotrexate	2.5 mg	BR	28
76813	9/1/00	Coumadin	2.5 mg	BR	30
76814	9/1/00	Radiacare Gel	4x4 sheet	BR	90
76815	9/1/00	OxyContin	40 mg	BR	90
82872	11/29/00	furosemide	40 mg	BR	60
82873	11/29/00	propranolol hydrochloride	40 mg	BR	90
82874	11/29/00	methotrexate	2.5 mg	BR	16
82875	11/29/00	azathioprine	50 mg	BR	15
82876	11/29/00	OxyContin	40 mg	BR	60
82877	11/29/00	OxyContin	80 mg	BR	6
83699	12/9/00	prednisone	10 mg	BR	30
83700	12/9/00	Radiacare Gel	4x4 sheet	BR	10
83701	12/9/00	OxyContin	80 mg	BR	28
84684	12/22/00	propranolol hydrochloride	40 mg	BR	90
84685	12/22/00	Deltasone	5 mg	BR	60
84686	12/22/00	furosemide	40 mg	BR	60
84687	12/22/00	OxyContin	80 mg	BR	12
84688	12/22/00	OxyContin	40 mg	BR	60
86640	1/20/01	propranolol hydrochloride	40 mg	BR	90
86641	1/20/01	furosemide	40 mg	BR	30
86642	1/20/01	OxyContin	80 mg	BR	20
87114	1/27/01	azathioprine	50 mg	JH	15
87115	1/27/01	OxyContin	40 mg	JH	30
87512	2/1/01	OxyContin	80 mg	JH	5
87520	2/2/01	warfarin sodium	2.5 mg	JH	30
87521	2/2/01	methotrexate	2.5 mg	JH	28
87522	2/2/01	quinine sulfate	260 mg	JH	30
87643	2/3/01	methadone hydrochloride	10 mg	BR	100
88196	2/10/01	propranolol hydrochloride	40 mg	JH	90
88197	2/10/01	OxyContin	80 mg	JH	15
88507	2/14/01	OxyContin	40 mg	JH	30
88508	2/14/01	azathioprine	50 mg	JH	15
88741	2/16/01	Prozac Pulvules	20 mg	BR	30
88742	2/16/01	Radiacare Gel	4x4 sheet	BR	90
88743	2/16/01	methadone hydrochloride	10 mg	BR	100
88744	2/16/01	OxyContin	80 mg	BR	15
89128	2/22/01	furosemide	40 mg	BR	30
89129	2/22/01	OxyContin	80 mg	BR	24
89625	3/1/01	propranolol hydrochloride	40 mg	BR	90
89626	3/1/01	OxyContin	80 mg	BR	24
89836	3/3/01	Deltasone	5 mg	BR	100
89837	3/3/01	methadone hydrochloride	10 mg	BR	100
90331	3/10/01	OxyContin	80 mg	JH	15
90332	3/10/01	methadone hydrochloride	10 mg	JH	100
90710	3/16/01	Deltasone	5 mg	BR	100
90711	3/16/01	OxyContin	80 mg	BR	16
90836	3/17/01	warfarin sodium	2.5 mg	BR	30
90837	3/17/01	methadone hydrochloride	10 mg	BR	100
90838	3/17/01	OxyContin	40 mg	BR	24
91212	3/22/01	azathioprine	50 mg	BR	15
91213	3/22/01	OxyContin	80 mg	BR	16
91342	3/24/01	propranolol hydrochloride	40 mg	JH	100
91343	3/24/01	methadone hydrochloride	10 mg	JH	100
91344	3/24/01	OxyContin	40 mg	JH	28
91702	3/29/01	OxyContin	80 mg	JH	5
91710	3/30/01	propranolol hydrochloride	40 mg	JH	100
91711	3/30/01	methadone hydrochloride	10 mg	JH	100
91960	4/2/01	Prozac Pulvules	20 mg	BR	10
91966	4/2/01	OxyContin	80 mg	BR	16
92194	4/5/01	OxyContin	40 mg	BR	40
92384	4/7/01	OxyContin	80 mg	JH	20
92385	4/7/01	furosemide	40 mg	JH	60
92386	4/7/01	quinine sulfate	260 mg	JH	30
92784	4/13/01	methadone hydrochloride	10 mg	JH	100
92842	4/13/01	OxyContin	40 mg	BR	40
92843	4/13/01	Prozac Pulvules	20 mg	BR	30
93065	4/17/01	propranolol hydrochloride	40 mg	JH	100
93066	4/17/01	OxyContin	80 mg	JH	24
94117	4/20/01	warfarin sodium	2.5 mg	JH	30
94118	4/20/01	methadone hydrochloride	10 mg	JH	100
94142	4/21/01	furosemide	40 mg	JH	60
94143	4/21/01	OxyContin	80 mg	JH	24
94328	4/24/01	OxyContin	40 mg	DDK	40
94595	4/27/01	OxyContin	80 mg	KJS	28
94597	4/27/01	quinine sulfate	260 mg	KJS	30
94598	4/27/01	azathioprine	50 mg	KJS	30
94620	4/28/01	methadone hydrochloride	10 mg	JH	100
94621	4/28/01	OxyContin	40 mg	JH	40
93065	5/4/01	propranolol hydrochloride	40 mg	JH	100
95079	5/4/01	methadone hydrochloride	10 mg	JH	100
95080	5/4/01	OxyContin	40 mg	JH	40
95335	5/8/01	warfarin sodium	2 mg	DDK	30
95336	5/8/01	OxyContin	80 mg	DDK	36
95529	5/11/01	OxyContin	40 mg	KJS	60
95531	5/11/01	warfarin sodium	2 mg	KJS	30
95532	5/11/01	Prozac Pulvules	20 mg	KJS	30
95586	5/12/01	quinine sulfate	260 mg	BR	30
95587	5/12/01	OxyContin	80 mg	BR	38
95821	5/15/01	furosemide	40 mg	JH	60
95822	5/15/01	OxyContin	80 mg	JH	36
95989	5/17/01	Lonox	2.5/0.025	BR	60
95990	5/17/01	methadone hydrochloride	10 mg	BR	100
95991	5/17/01	OxyContin	40 mg	BR	15
96167	5/21/01	azathioprine	50 mg	BR	15
96168	5/21/01	OxyContin	80 mg	BR	36
96334	5/23/01	propranolol hydrochloride	40 mg	BR	90
96335	5/23/01	OxyContin	40 mg	BR	60
96421	5/24/01	prednisone	5 mg	JH	90
96422	5/24/01	furosemide	40 mg	JH	60
96423	5/24/01	OxyContin	80 mg	JH	15
96424	5/24/01	methadone hydrochloride	10 mg	JH	100
96645	5/29/01	OxyContin	80 mg	JH	36
96920	6/1/01	OxyContin	40 mg	JH	36
96921	6/1/01	methadone hydrochloride	10 mg	JH	100
96922	6/1/01	Lonox	2.5/0.025	JH	60
96923	6/1/01	azathioprine	50 mg	JH	15
97100	6/4/01	OxyContin	80 mg	BR	20
97309	6/6/01	Amoxicillin	500 mg	BR	28
97310	6/6/01	OxyContin	80 mg	BR	30
97456	6/8/01	furosemide	40 mg	BR	60
97457	6/8/01	methadone hydrochloride	10 mg	BR	100
97582	6/11/01	Prozac Pulvules	90 mg	BR	4
97583	6/11/01	OxyContin	40 mg	BR	60
97740	6/13/01	Levaquin	250 mg	BR	3
97741	6/13/01	OxyContin	80 mg	BR	36
97813	6/14/01	methadone hydrochloride	10 mg	JH	100
98007	6/18/01	quinine sulfate	260 mg	BR	30
98008	6/18/01	OxyContin	40 mg	BR	60
98145	6/20/01	OxyContin	80 mg	BR	36
98236	6/21/01	methadone hydrochloride	10 mg	JH	100
98330	6/23/01	MS Contin	60 mg	BR	60
98331	6/23/01	furosemide	40 mg	BR	60
98448	6/25/01	OxyContin	80 mg	JH	36
98449	6/25/01	azathioprine	50 mg	JH	15
98607	6/27/01	propranolol hydrochloride	40 mg	BR	90
98608	6/27/01	OxyContin	40 mg	BR	36
98609	6/27/01	methadone hydrochloride	10 mg	BR	120
98792	6/30/01	OxyContin	80 mg	JH	36
98793	6/30/01	warfarin sodium	2 mg	JH	30
98885	7/2/01	methadone hydrochloride	10 mg	JH	100
98886	7/2/01	prednisone	5 mg	JH	100
98968	7/3/01	OxyContin	40 mg	JH	50
99143	7/6/01	Prozac Pulvules	20 mg	BR	30
99144	7/6/01	quinine sulfate	260 mg	BR	30
99146	7/6/01	methadone hydrochloride	10 mg	BR	100
99278	7/10/01	methadone hydrochloride	10 mg	BR	100
99569	7/13/01	prednisone	5 mg	JH	100
99570	7/13/01	OxyContin	80 mg	JH	36
99686	7/16/01	OxyContin	40 mg	BR	36
99707	7/17/01	methadone hydrochloride	10 mg	BR	100
99914	7/19/01	furosemide	40 mg	JH	60
99915	7/19/01	methadone hydrochloride	10 mg	JH	120
100103	7/23/01	propranolol hydrochloride	40 mg	JH	90
100104	7/23/01	methadone hydrochloride	10 mg	JH	100
100335	7/27/01	warfarin sodium	2 mg	BR	30
100336	7/27/01	methadone hydrochloride	10 mg	BR	200
100693	8/2/01	Prozac Pulvules	20 mg	BR	7
100694	8/2/01	azathioprine	50 mg	BR	15
100695	8/2/01	methadone hydrochloride	10 mg	BR	200
101039	8/7/01	methadone hydrochloride	10 mg	JH	200
101040	8/7/01	fluoxetine	20 mg	JH	15
101338	8/13/01	methadone hydrochloride	10 mg	BR	200
101339	8/13/01	prednisone	5 mg	BR	100
101808	8/18/01	furosemide	40 mg	MC	30
101809	8/18/01	methadone hydrochloride	10 mg	MC	200
102165	8/23/01	methadone hydrochloride	10 mg	JH	200
102304	8/27/01	OxyContin	80 mg	BR	10
101040	8/31/01	fluoxetine	20 mg	MC	15
102767	8/31/01	methadone hydrochloride	10 mg	MC	200
103215	9/6/01	methadone hydrochloride	10 mg	JH	200
103376	9/8/01	furosemide	40 mg	JH	30
103377	9/8/01	OxyContin	80 mg	JH	20
103446	9/10/01	Propranolol hydrochloride	40 mg	MC	120
103914	9/14/01	methadone hydrochloride	10 mg	MC	200
103915	9/14/01	fluoxetine	20 mg	MC	15
104248	9/19/01	OxyContin	40 mg	MC	48
104249	9/19/01	azathioprine	50 mg	MC	15
104330	9/20/01	methadone hydrochloride	10 mg	JH	200
104646	9/25/01	OxyContin	80 mg	JH	28
104803	9/27/01	methadone hydrochloride	10 mg	JH	200
104804	9/27/01	OxyContin	40 mg	JH	28
104805	9/27/01	fluoxetine	20 mg	JH	30
104806	9/27/01	warfarin sodium	2 mg	JH	30
103446	10/3/01	propranolol hydrochloride	40 mg	MC	120
105194	10/3/01	methadone hydrochloride	10 mg	MC	200
105526	10/9/01	furosemide	40 mg	MC	30
105527	10/9/01	warfarin sodium	2 mg	MC	30
105528	10/9/01	methadone hydrochloride	10 mg	MC	200
105887	10/15/01	fluoxetine	20 mg	BR	30
105888	10/15/01	azathioprine	50 mg	BR	15
105889	10/15/01	methadone hydrochloride	10 mg	BR	200
105890	10/15/01	OxyContin	40 mg	BR	24
106292	10/19/01	methadone hydrochloride	10 mg	BR	200
106771	10/27/01	propranolol hydrochloride	40 mg	MC	100
106772	10/27/01	methadone hydrochloride	10 mg	MC	200
107156	11/2/01	methadone hydrochloride	10 mg	MC	200
107579	11/8/01	fluoxetine	20 mg	JH	30
107580	11/8/01	methadone hydrochloride	10 mg	JH	200
107962	11/14/01	furosemide	40 mg	MC	30
107963	11/14/01	methadone hydrochloride	10 mg	MC	200
108484	11/21/01	methadone hydrochloride	10 mg	MC	200
108485	11/21/01	OxyContin	80 mg	MC	16
108759	11/27/01	methadone hydrochloride	10 mg	JH	200
108760	11/27/01	propranolol hydrochloride	40 mg	JH	100
109116	12/1/01	methadone hydrochloride	10 mg	JH	200
109117	12/1/01	fluoxetine	20 mg	JH	30
109513	12/6/01	OxyContin	80 mg	JH	15
109514	12/6/01	methadone hydrochloride	10 mg	JH	200
109859	12/11/01	methadone hydrochloride	10 mg	JH	200
109860	12/11/01	warfarin sodium	2.5 mg	JH	30
110116	12/14/01	methadone hydrochloride	10 mg	BR	200
110540	12/20/01	methadone hydrochloride	10 mg	JH	200
110752	12/24/01	furosemide	40 mg	BR	30
110753	12/24/01	methadone hydrochloride	10 mg	BR	200
111004	12/28/01	methadone hydrochloride	10 mg	MC	200
111280	1/2/02	fluoxetine	20 mg	JH	15
111281	1/2/02	Dolophine Hydrochloride	10 mg	JH	200
111282	1/2/02	OxyContin	80 mg	JH	10
111280	1/7/02	fluoxetine	20 mg	MC	10
111662	1/7/02	methadone hydrochloride	10 mg	MC	200
108760	1/12/02	propranolol hydrochloride	40 mg	JH	30
112050	1/12/02	methadone hydrochloride	10 mg	JH	200
112372	1/17/02	methadone hydrochloride	10 mg	JH	200
112373	1/17/02	fluoxetine	20 mg	JH	12
112740	1/23/02	methadone hydrochloride	10 mg	MC	200
108760	1/28/02	propranolol hydrochloride	40 mg	MC	20
112993	1/28/02	methadone hydrochloride	10 mg	MC	200
113287	1/31/02	OxyContin	80 mg	JH	40
113734	2/6/02	methadone hydrochloride	10 mg	MC	200
113735	2/6/02	propranolol hydrochloride	40 mg	MC	60
114155	2/12/02	methadone hydrochloride	10 mg	JH	200
112373	2/16/02	fluoxetine	20 mg	MC	60
114436	2/16/02	methadone hydrochloride	10 mg	MC	200
114806	2/21/02	methadone hydrochloride	10 mg	MC	200
114807	2/26/02	propranolol hydrochloride	40 mg	JH	45
115118	2/26/02	methadone hydrochloride	10 mg	JH	200
115360	3/2/02	methadone hydrochloride	10 mg	MC	100
115624	3/6/02	methadone hydrochloride	10 mg	MC	200
112373	3/11/02	fluoxetine	20 mg	MC	60
115969	3/11/02	methadone hydrochloride	10 mg	MC	200
116311	3/16/02	methadone hydrochloride	10 mg	MC	200
114807	3/22/02	propranolol hydrochloride	40 mg	MC	15
116762	3/22/02	methadone hydrochloride	10 mg	MC	200
117031	3/28/02	methadone hydrochloride	10 mg	MC	200
117032	3/28/02	propranolol hydrochloride	40 mg	MC	90
117347	4/3/02	methadone hydrochloride	10 mg	MC	200
117611	4/6/02	methadone hydrochloride	10 mg	JH	200
117612	4/6/02	fluoxetine	20 mg	JH	60

Such conduct is in violation of Rules 4729-5-20 and 4729-5-22 of the Ohio Administrative Code.

Kevin John Snyder neither admits nor denies the allegations stated in the amended Notice of Opportunity for Hearing letter however, the Board has evidence sufficient to sustain the allegations and hereby adjudicates the same.

Wherefore, in consideration of the foregoing and mutual promises hereinafter set forth, and in lieu of a formal hearing at this time, Kevin John Snyder knowingly and voluntarily agrees with the State Board of Pharmacy to the following:

(A) Kevin John Snyder agrees to the imposition of a monetary penalty of Five Hundred Dollars ($500.00) due and owing within 30 days of the effective date of this Agreement. The monetary penalty should be made payable to the “Treasurer, State of Ohio” and mailed with the enclosed form to the State Board of Pharmacy, 77 S. High Street, 17th Floor, Columbus, Ohio 43215-6126.

Kevin John Snyder acknowledges that he has had an opportunity to ask questions concerning the terms of this agreement and that all questions asked have been answered in a satisfactory manner. Any action initiated by the Board based on alleged violation of this Agreement shall comply with the Administrative Procedure Act, Chapter 119. of the Ohio Revised Code.

Kevin John Snyder waives any and all claims or causes of action he may have against the State of Ohio or the Board, and members, officers, employees, and/or agents of either, arising out of matters which are the subject of this Agreement. Kevin John Snyder waives any rights of appeal pursuant to Chapter 119. of the Ohio Revised Code.

This Settlement Agreement shall be considered a public record, as that term is used in Section 149.43 of the Ohio Revised Code, and shall become effective upon the date of the Board President’s signature below.

/s/          Kevin John Snyder	/d/   05–24–2003
Kevin John Snyder, Respondent	Date of Signature
/s/          Diane C. Adelman	/d/      6/2/03
Diane C. Adelman, President, Ohio State Board of Pharmacy	Date of Signature
/s/          Sally Ann Steuk	/d/      6–2–03
Sally Ann Steuk, Ohio Assistant Attorney General	Date of Signature

R-2003-184

SETTLEMENT AGREEMENT WITH THE STATE BOARD OF PHARMACY (Docket No. D-030109-052) In The Matter Of: AUDLEY D. STEVENS, R.Ph. 1269 Washington Street Box 293 Conneautville, PA 16406 (R.Ph. No. 03-2-07168) This Settlement Agreement is entered into by and between Audley D. Stevens and the Ohio State Board of Pharmacy, a state agency charged with enforcing the Pharmacy Practice Act and Dangerous Drug Distribution Act, Chapter 4729. of the Ohio Revised Code. Audley D. Stevens voluntarily enters into this Agreement being fully informed of his rights afforded under Chapter 119. of the Ohio Revised Code, including the right to representation by counsel, the right to a formal adjudication hearing on the issues contained herein, and the right to appeal. Audley D. Stevens acknowledges that by entering into this agreement he has waived his rights under Chapter 119. of the Revised Code. Whereas, the Board is empowered by Section 4729.16 of the Ohio Revised Code to suspend, revoke, place on probation, refuse to grant or renew an identification card or enforce a monetary penalty on the license holder for violation of any of the enumerated grounds therein. Whereas, Audley D. Stevens is licensed to practice pharmacy in the State of Ohio. Whereas, on or about January 9, 2003, pursuant to Chapter 119. of the Ohio Revised Code, Audley D. Stevens was notified of the allegations or charges against him, his right to a hearing, his rights in such hearing, and his right to submit contentions in writing. Audley D. Stevens requested a hearing; it was scheduled and continued. The January 9, 2003, Notice of Opportunity for Hearing contains the following allegations or charges:

(1)	Records of the Board of Pharmacy indicate that Audley D. Stevens was originally licensed in the State of Ohio on March 8, 1960, pursuant to reciprocity, and is currently licensed to practice pharmacy in the State of Ohio.
(2)	Audley D. Stevens did, on or about July 5, 1996, knowingly make a false statement with purpose to secure the issuance of a license or registration, to wit: Audley D. Stevens indicated on his pharmacist license renewal application that he had not been subject of a disciplinary action by any state or federal agency. On or about May 30, 1996, Audley D. Stevens pled guilty to Mail Fraud, a felony, in violation of 18 U.S.C. §1341. United States of America vs. Audley Stevens, Criminal No. 96-15, U.S. District For Western District of Pennsylvania. Such conduct is in violation of Section 2921.13 of the Ohio Revised Code.
(3)	On May 30, 1996, Audley D. Stevens pled guilty to Mail Fraud, a felony, in violation of 18 U.S.C. §1341. United States of America vs. Audley Stevens, Criminal No. 96-15, U.S. District For Western District of Pennsylvania.

Audley D. Stevens neither admits nor denies the allegations stated in the Notice of Opportunity for Hearing letter dated January 9, 2003; however, the Board has evidence sufficient to sustain the allegations and hereby adjudicates the same:

Wherefore, in consideration of the foregoing and mutual promises hereinafter set forth, and in lieu of a formal hearing at this time, Audley D. Stevens knowingly and voluntarily agrees with the State Board of Pharmacy to the following:

(A)	Audley D. Stevens’ pharmacist identification card, No. 03-2-07168, will be suspended for one year from the effective date of this Agreement.
(B)	Audley D. Stevens license to practice pharmacy will be reinstated following the suspension with the following conditions:

(1)	Audley D. Stevens’ pharmacist identification card is not in good standing and thereby denies the privilege of being a preceptor and training pharmacy interns pursuant to paragraph (D)(1) of Rule 4729-3-01 of the Ohio Administrative Code.
(2)	Audley D. Stevens may not serve as a responsible pharmacist.

If, in the judgment of the Board, Audley D. Stevens appears to have violated or breached any terms or conditions of this Agreement, the Ohio State Board of Pharmacy reserves the right to, at any time, revoke probation, modify the conditions of probation, and reduce or extend the period of probation, and/or the Board may institute formal disciplinary proceedings for any and all possible violations or breaches, including but not limited to, alleged violation of the laws of Ohio occurring before the effective date of this Agreement.

Audley D. Stevens acknowledges that he has had an opportunity to ask questions concerning the terms of this agreement and that all questions asked have been answered in a satisfactory manner. Any action initiated by the Board based on alleged violation of this Agreement shall comply with the Administrative Procedure Act, Chapter 119. of the Ohio Revised Code.

Audley D. Stevens waives any and all claims or causes of action he may have against the State of Ohio or the Board, and members, officers, employees, and/or agents of either, arising out of matters which are the subject of this Agreement. Audley D. Stevens waives any rights of appeal pursuant to Chapter 119. of the Ohio Revised Code.

This Settlement Agreement shall be considered a public record, as that term is used in Section 149.43 of the Ohio Revised Code, and shall become effective upon the date of the Board President’s signature below.

/s/          Audley D. Stevens	/d/   5/27/2003
Pharmacist Audley D. Stevens, Respondent	Date of Signature
/s/          Douglas Graff	/d/   5/30/2003
Douglas Graff, Attorney for Respondent	Date of Signature
/s/          Diane C. Adelman	/d/      6/2/03
Diane C. Adelman, President, Ohio State Board of Pharmacy	Date of Signature
/s/          Sally Ann Steuk	/d/      6–2–03
Sally Ann Steuk, Ohio Assistant Attorney General	Date of Signature

R-2003-185	Mr. Turner moved that the settlement request for Philip Charles Garber be denied and the hearing be continued until his sentencing of federal charges is complete. The motion was seconded by Mr. Giacalone and approved by the Board (Aye-4/Nay-3/Abstain-1[Braylock]).
R-2003-186	Mr. Kost moved that, pursuant to the Board Order of June 10, 2002 for Vernon Infantino, compliance with the Board's Order will require twelve months of urine screens testing for pemoline. The motion was seconded by Ms. Eastman and approved by the Board (Aye-5/Nay-1/Abstain-2[Braylock,Gregg]).
R-2003-187	Mrs. Teater moved that the Board renew the contract with the Attorney General's office to provide the Board with full-time counsel, Sally Ann Steuk. The motion was seconded by Mr. Turner and approved by the Board (Aye-8/Nay-0).

11:40 a.m.

The Board recessed for lunch.

1:13 p.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of creating a record in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Mark Lawrence Iori, Intern, Batavia.

1:25 p.m.

The hearing ended and the record was closed. The Board took a brief recess.

1:37 p.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Joseph M. Rukse, R.Ph., Huntington, West Virginia.

3:30 p.m.

The hearing ended and the record was closed. The Board took a brief recess.

3:40 p.m.

Mr. Keeley presented the draft rules for H.B. 221, the Drug Repository bill, developed by the Board's ad hoc committee assigned to write these rules.

4:53 p.m.

R-2003-188

Mr. Keeley presented a request from Knox Community Hospital (02-0039100) for an exemption to Rule 4729-5-10 (Pick-up station) so that patient-specific prescriptions could be prepared at Paragon Scientific in Austin, Texas (02-1066950) and delivered to Knox Community Hospital for distribution to the patients. After discussion, Mrs. Gregg moved that the Board approve the request due to the need for involvement by a health care professional in the patient’s drug therapy [OAC Rule 4729-5-10(B)(5)(b)]. The motion was seconded by Mr. Braylock and approved by the Board (Aye-8/Nay-0).

5:05 p.m.

R-2003-189

Mr. Keeley presented information on eInformatics for approval as an electronic prescription transmission system. Mrs. Gregg moved that the Board give eInformatics an approvable status pending review by the field staff at the first installation location. The motion was seconded by Mr. Kost and approved by the Board (Aye-8/Nay-0).

5:15 p.m.

Mrs. Gregg moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code. The motion was seconded by Mr. Giacalone and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.

5:27 p.m.

R-2003-190	The Executive Session ended and the meeting was opened to the public. Ms. Eastman moved that the Board adopt the following Order in the matter of Mark Lawrence Iori:
	ORDER OF THE STATE BOARD OF PHARMACY (Docket No. D-030415-066) In The Matter Of: MARK LAWRENCE IORI 4483 Eastwood Drive, #17112 Batavia, Ohio 45103 (Pharmacy Intern No. 06-0-03343) INTRODUCTION THE MATTER OF MARK LAWRENCE IORI CAME FOR CONSIDERATION ON JUNE 2, 2003, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; LAWRENCE J. KOST, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph. MARK LAWRENCE IORI WAS NOT PRESENT NOR WAS HE REPRESENTED BY COUNSEL AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.
	SUMMARY OF EVIDENCE State’s Witnesses 1. Kevin J. Kinneer, Ohio State Board of Pharmacy Respondent's Witnesses None State's Exhibits 1. Copy of Notice of Opportunity For Hearing [04-15-03] 1A. Procedural 2. Copy of Renewal Application for Intern License of Mark Lawrence Iori [08-01-01] 2A. Copy of Application for Pharmacy Intern Registration of Mark Lawrence Iori [06-26-01]; Copy of University of Cincinnati Transcript for Mark L. Iori [06-11-01] 3. Letter of Registration from William F. McMillen, R.Ph. [07-16-01] 4. Notarized Statement of Jeff Hogrefe, R.Ph. [02-13-03] 5. SuperValu Ban Agreement re Amy M. Iori [09-15-02]; Copy of Statement of Amy M. Iori [09-15-02] 6. Copy of Statement of Mark Iori [09-15-02] 7. Monthly Breakdown of Mark Iori’s Returns [04-01 to 09-02] 8. Indictment, State of Ohio vs. Mark Lawrence Iori, Case No. 02-CR-00620, Clermont County Common Pleas Court [10-02-02] 9. Written Plea of Guilty [11-27-02] 10. Judgment Entry Sentencing Defendant To Community Control [01-09-03] Respondent's Exhibits None
	FINDINGS OF FACT After having heard the testimony, observed the demeanor of the witness, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to be fact:
	(1) On April 15, 2003, Mark Lawrence Iori was notified by letter of his right to a hearing, his rights in such hearing, and his right to submit his contentions in writing. (2) As demonstrated by return receipt dated April 22, 2003, Mark Lawrence Iori received the letter of April 15, 2003, informing him of the allegations against him, and his rights. (3) Mark Lawrence Iori has not responded in any manner to the letter of April 15, 2003, and has not requested a hearing in this matter. (4) Records of the State Board of Pharmacy indicate that Mark Lawrence Iori was originally licensed by the State of Ohio as a pharmacy intern on June 29, 2001. (5) Mark Lawrence Iori did, from April, 2001, through September, 2002, with purpose to deprive, knowingly obtain or exert control over cash money, the property of Bigg's Pharmacy, by deception, to wit: Mark Lawrence Iori admittedly stole $14,756.94 through a scheme of creating false refunds and pocketing the cash from his employer. Such conduct is in violation of Section 2913.02 of the Ohio Revised Code. (6) On or about November 26, 2002, Mark Lawrence Iori pled to one count of Theft, a felony of the fourth degree, under Section 2913.02(A)(1) of the Ohio Revised Code. On January 6, 2003, Mark Lawrence Iori was sentenced to five years of community control with conditions. State of Ohio vs. Mark Lawrence Iori, Case No. 02-CR-00620, Clermont County Common Pleas Court.
	CONCLUSIONS OF LAW (1) The State Board of Pharmacy concludes that paragraphs (5) and (6) of the Findings of Fact constitute being guilty of a felony and gross immorality as provided in Division (A)(1) of Section 4729.16 of the Ohio Revised Code. (2) The State Board of Pharmacy concludes that paragraphs (5) and (6) of the Findings of Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.
	DECISION OF THE BOARD Pursuant to Section 4729.16 of the Ohio Revised Code, and after consideration of the record as a whole, the State Board of Pharmacy hereby revokes the pharmacy intern identification card, No. 06-0-03343, held by Mark Lawrence Iori effective as of the date of the mailing of this Order. THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY. MOTION CARRIED. SO ORDERED. The motion was seconded by Mr. Turner and approved by the Board (Aye-8/Nay-0).

5:30 p.m.

The meeting recessed until Tuesday, June 3, 2003.

TUESDAY, JUNE 3, 2003

8:31 a.m.

ROLL CALL

The State Board of Pharmacy convened in Room West-B&C, 31st Floor, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio with the following members present:

Diane C. Adelman, R.Ph. (President); Robert P. Giacalone, R.Ph. (Vice-President); Elizabeth I. Gregg, R.Ph.; Lawrence J. Kost, R.Ph.; Nathan S. Lipsyc, R.Ph.; Dorothy S. Teater, Public Member; and James E. Turner, R.Ph.

8:32 a.m.

Mrs. Gregg moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code. The motion was seconded by Mr. Lipsyc and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.

8:35 a.m.

Board Member Suzanne R. Eastman, R.Ph. arrived and joined the Executive Session in progress.

9:00 a.m.

R-2003-191

The Executive Session ended and the meeting was opened to the public. Mr. Giacalone moved that the Board accept the settlement offer in the matter of Rayner B. Lotton, R.Ph. The motion was seconded by Mr. Kost and approved by the Board (Aye-5/Nay-4).

9:08 a.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Matthew Donavon Nourse, R.Ph., Lucasville.

10:56 a.m.

The hearing ended and the record was closed.

11:02 a.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Loretta Ann Nehez, R.Ph., Ukiah, California.

11:46 a.m.

The hearing ended and the record was closed.

11:52 a.m.

Mr. Lipsyc moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code. The motion was seconded by Mrs. Gregg and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.

12:02 p.m.

R-2003-192	The Executive Session ended and the meeting was opened to the public. Ms. Eastman moved that the Board adopt the following Order in the matter of Loretta Ann Nehez: ORDER OF THE STATE BOARD OF PHARMACY (Docket No. D-030307-062) In The Matter Of: LORETTA ANN NEHEZ, R.Ph. 3620 Eastside Calpella Road Ukiah, California 95482 (D.O.B. 10/08/1954)
	INTRODUCTION THE MATTER OF LORETTA ANN NEHEZ CAME FOR HEARING ON JUNE 3, 2003, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; LAWRENCE J. KOST, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph. LORETTA ANN NEHEZ WAS NOT REPRESENTED BY COUNSEL AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.
	SUMMARY OF EVIDENCE State’s Witnesses 1. Loretta A. Nehez, R.Ph., Respondent Respondent's Witnesses None
	State's Exhibits 1. Copy of Proposal to Deny/Notice of Opportunity For A Hearing [03-07-03] 1A-1B. Procedurals 2. NABP Official Application for Transfer of Pharmaceutic Licensure of Loretta Ann Nehez [12-9-02] 3. Accusation, In the Matter of Loretta Ann Nehez, Case No. 1573, State of California Board of Pharmacy, Dept. of Consumer Affairs [09-26-91] 4. Stipulation [05-12-94]
	Respondent's Exhibits A. Opening Statement of Loretta Nehez [not dated] B. Copy of letter from Robert W. Stewart [05-14-03] C. Order for Drug Diversion, The People Of The State of California vs. Loretta Ann Nehez, Case No. WC1255, The Mt. Sanhedrin Judicial District Municipal Court [03-06-91]; Notice, Sentence, Commitment Form [03-06-91] D. Complaint-Criminal Felony [01-08-91] E. Copy of Treatment Evaluation from Deborah L. Jaynes, M.A. [10-11-93] F. Order To Dismiss Complaint [04-28-94]; Notice, Sentence, Commitment Form [08-28-91] G. Copy of Compliance letter from Jon Thayer M.A., R.N., CARN, C.D. [05-10-93] H. Copy of Compliance letter from Jon Thayer M.A., R.N., CARN, C.D. [07-12-94] I. Copy of Treatment Contract letter from Maureen F. Whitmore, M.A., M.F.C.C. [04-11-91]; Copy of Impaired Pharmacist Program Treatment Contract of Loretta Nehez [04-17-91] J. Copy of letter from M. Michele Scantlebury, R.N., M.S.N., C.S. [08-07-91]; Copy of Addendum #1 to Pharmacist Recovery Program of Loretta Nehez [08-13-91] K. Copy of letter from M. Michele Scantlebury, R.N., M.S.N., C.S. [01-08-92]; Copy of Addendum #2 to Pharmacist Recovery Program of Loretta Nehez [01-10-92] L. Copy of letter from M. Michele Scantlebury, R.N., M.S.N., C.S. [04-20-92]; Copy of Addendum #3 to Pharmacist Recovery Program of Loretta Nehez [04-21-92] M. Copy of letter from M. Michele Scantlebury, R.N., M.S.N., C.S. [06-24-92]; Copy of Addendum #4 to Pharmacist Recovery Program of Loretta Nehez [07-01-92] N. Copy of letter from M. Michele Scantlebury, R.N., M.S.N., C.S. [12-02-92]; Copy of Addendum #5 to Pharmacist Recovery Program of Loretta Nehez [12-09-92] O. Copy of letter from Jon Thayer, M.A., R.N., C.A.R.N., C.D. [06-22-93]; Copy of Addendum #6 to Pharmacist Recovery Program of Loretta Nehez [07-03-93] P. Copy of letter from Jon Thayer, M.A., R.N., C.A.R.N., C.D. [12-30-93]; Copy of Addendum #7 to Pharmacist Recovery Program of Loretta Nehez [01-21-94] Q. Copy of Individual Reassessment Form of Loretta Nehez [11-20-91] R. Copy of Individual Reassessment Form of Loretta Nehez [05-08-92] S. Copy of faxed letter to Michele Scantlebury from Loretta Nehez [04-29-92] T. Copy of faxed letter to Michele Scantlebury from Loretta Nehez [07-11-92] U. Copy of two letters to Occupational Health Services, Inc. from Loretta Nehez [10-03-93] V. Copy of California State Board of Pharmacy Probation Termination letter from Robert Ratcliff by Anne Farrenkopf [06-12-97] W. Copy of letter from Patricia F. Harris [04-13-94]; Stipulation, In the Matter of the Accusation Against Loretta Ann Nehez, No. 1573, Board of Pharmacy, Department of Consumer Affairs, State of California [08-03-93] X. Accusation [09-26-91] Y. Copy of letter from Raymond Tom [04-14-94] Z. Copy of letter from Loretta Nehez [04-01-97] AA-II. Copy of nine Letters of Support [05-20-03 to 05-22-03]
	FINDINGS OF FACT After having heard the testimony, observed the demeanor of the witness, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to be fact:
	(1) Loretta Ann Nehez is a registered pharmacist in the states of California and Indiana, and on or about November 20, 2002, Loretta Ann Nehez submitted an application for registration as a pharmacist by reciprocity to the State of Ohio. (2) Loretta Ann Nehez's license to practice pharmacy in California was, on or about August 3, 1993, revoked; the revocation was stayed and Ms. Nehez was placed on probation for three years with conditions relative to her thefts of dangerous drugs and controlled substances for her own abuse. (3) Loretta Ann Nehez's probation was officially terminated and her pharmacist license fully restored by the California State Board of Pharmacy effective May 12, 1997
	DECISION OF THE BOARD Pursuant to Section 4729.09 of the Ohio Revised Code, and after consideration of the record as a whole, the State Board of Pharmacy hereby approves the issuance of a pharmacist identification card to Loretta Ann Nehez to practice pharmacy in Ohio and, therefore, accepts the Official Application for Transfer of Pharmaceutic Licensure submitted by Loretta Ann Nehez and received by the Board on December 9, 2002. Further, Loretta Ann Nehez must notify the Ohio State Board of Pharmacy prior to employment in Ohio. THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY. MOTION CARRIED. SO ORDERED.
	The motion was seconded by Mr. Turner and approved by the Board (Aye-8/Nay-0).

12:05 p.m.

The Board recessed for lunch and the Board’s meeting with the reciprocity candidates.

1:30 p.m.

	With all members present, the Board convened in Room South-A, 31st Floor, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio, for the purpose of meeting with the candidates for licensure by reciprocity.
R-2003-193	Following presentations by Board members and self-introductions by the candidates for licensure by reciprocity, the following candidates participated in a discussion of pharmacy laws and rules with Mr. McMillen and were then presented with their Ohio pharmacist identification cards.

CYBIL I. ADWELL JOSEPH BERNARD BLAIR SUSAN MARGARET CROWE JESSICA JOY ELLIS GENNET A. GEBRE-MICHAEL JAMES M. HOFFER ENDALISH MULUGETA-PRYOR LORETTA ANN NEHEZ OKECHUKWU OJUKWU HOLLY LANET POOLE REBECCA ANN TALBERT ABIGAIL MEREDITH WOODLAND

03-3-25770 03-3-25669 03-3-25823 03-3-25807 03-3-25827 03-3-25748 03-3-25821 03-3-25573 03-3-25829 03-3-25775 03-3-25745 03-3-25824

PENNSYLVANIA NORTH DAKOTA MICHIGAN MICHIGAN MISSOURI PENNSYLVANIA KENTUCKY INDIANA MARYLAND TEXAS WEST VIRGINIA MISSOURI

1:48 p.m.

R-2003-194

Mr. Keeley presented a request from Scarbrough Medical Arts Pharmacy [02-0114850) for an exemption to Rule 4729-5-10 (Pick-up station) so that patient-specific prescriptions could be prepared at Scarbrough Medical Arts Pharmacy and delivered to East Columbus Surgery Center [02-1178400] and Findlay Surgery Center [02-1171400] for distribution to the patients. After discussion, Mrs. Gregg moved that the Board approve the request due to the need for involvement by a health care professional in the patient’s drug therapy [OAC Rule 4729-5-10(B)(5)(b)]. The motion was seconded by Mr. Turner and approved by the Board (Aye-8/Nay-0).

1:56 p.m.

After a discussion of the draft minutes from the May 12 & 13, 2003 meeting, Mr. Kost moved that the minutes be approved as amended. The motion was seconded by Ms. Eastman and approved by the Board (Aye-8/Nay-0).

After a discussion of the draft minutes from the May 19, 2003 telephone conference call, Mrs. Teater moved that the minutes be approved. The motion was seconded by Mr. Turner and approved by the Board (Aye-5/Nay-0/Abstain-3[Gregg,Kost,Lipsyc]).

2:03 p.m.

Mr. Braylock moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code. The motion was seconded by Mr. Turner and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.

2:52 p.m.

R-2003-195	The Executive Session ended and the meeting was opened to the public. Mr. Braylock moved that the Board adopt the following Order in the matter of Joseph H. Rukse: ORDER OF THE STATE BOARD OF PHARMACY (Docket No. D-001226-027) In The Matter Of: JOSEPH MARTIN RUKSE, JR., R.Ph. 23 Colonial Court Barboursville, West Virginia 25504 (R.Ph. No. 03-2-15318)
	INTRODUCTION THE MATTER OF JOSEPH MARTIN RUKSE, JR. CAME FOR HEARING ON JUNE 2, 2003, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; LAWRENCE J. KOST, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph. JOSEPH MARTIN RUKSE, JR. WAS REPRESENTED BY DOUGLAS E. GRAFF AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.
	SUMMARY OF EVIDENCE State’s Witnesses 1. Joseph Martin Rukse, Jr., R.Ph., Respondent Respondent's Witnesses 1. Annetta Spurlock
	State's Exhibits 1. Copy of Summary Suspension Order/Notice of Opportunity For Hearing [12-26-00] 1A-1K. Procedurals 2. Information, United States of America v. Joseph M. Rukse, Jr., Criminal No. 3:00-00219, U.S. District Court for the Southern District of West Virginia [10-11-00] 3. Letter of Agreement in re United States v. Joseph M. Rukse, Jr. [07-18-00] 4. Order [11-13-00] 5. Judgment in a Criminal Case [01-24-01] 6. Copy of State Board of Pharmacy Order in re Joseph Martin Rukse, Jr., R.Ph. [05-05-99] 7. Kmart Loss Control Report of Investigation [03-01-97] 8. Criminal Affidavit, Complaint By Prosecuting Attorney Upon Affidavit, and Judgement Entry of Plea and Sentencing, for Theft. State of Ohio vs. Joseph Rukse, Case No. 97-CRA-393, Lawrence County Municipal Court [04-29-97 to 06-02-97] 9. Standard Rules of Probation, Lawrence County Municipal Court [not dated] 10. Copy of Renewal Application for Pharmacist License of Joseph M. Rukse [07-15-97] 11. Complaint, State of Ohio v. Rukse, Case No. 98/013821, Franklin County Municipal Court [05-29-98] 12. Sentencing Entry [11-24-98] 13. Copy of letter from William T. Douglass, Jr. [04-23-02]
	Respondent's Exhibits A1. Support Group Attendance Records [05-19-00 to 04-22-03] A2. Copy of PRO Pharmacist’s Recovery Contract for Joseph Rukse [09-19-00]; Copy of PRO Pharmacist’s Recovery Contract for Joseph Rukse [06-21-02] A3. Twelve Statements of Account re Joseph M. Rukse, Jr. by the U.S. Department of Justice [12-14-01 to 04-04-03] A4. Thirty-two Continuing Pharmaceutical Education Certificates [05-21-02 to 04-27-03] A5. Letter from Frederick N. Karaffa, M.D. [12-29-00]; Letter from Steve Gifford, B.A., CCDC III-E [06-06-00] A6. Letter from Kelly M. Clark [03-26-02] A7. Letter from J. Thomas Jones [12-21-00] A8. Copy of letter from John Paull Hogg [12-15-00] A9. Letter from Dana D. Varney [03-02] A10. Letter from Karl S. Valentine, R.Ph. [04-29-03] A11. Letter from Bruce J. Merkin, M.D. [05-01-03] A12. Letter from Kimberly D. Holton [04-12-03] A13. Letter from Robert Holton [not dated] A14. Letter from Marshall T. Reynolds [04-24-03] A15. Letter from Randy Patrick [not dated] A16. Copy of Certificate of Achievement [07-13-01], Copies of four Program Review Reports re Joseph M. Rukse, Jr. [03-02-01 to 11-09-01] A17. Copy of Facsimile Transmission Form from the United States Probation Office to Graff & Associates, L.P.A. [05/30/03], Drug Screen Reports [03-22-02 to 03-26-03] A18. Drug Screen Reports [01-22-02 to 03-11-02] A19. Drug Screen Reports [09-28-00 to 02-08-01] A20. U.S. Department of Justice Statement of Account re Joseph M. Rukse, Jr. [05-19-03]
	FINDINGS OF FACT After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to be fact:
	(1) Records of the State Board of Pharmacy indicate that Joseph Martin Rukse, Jr. was originally licensed by the State of Ohio as a pharmacist on September 27, 1983, pursuant to reciprocity, and that his license to practice pharmacy in Ohio was summarily suspended effective December 26, 2000. (2) Joseph Martin Rukse, Jr. is addicted to liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy, to wit: Joseph Martin Rukse, Jr. has admitted that he has a chemical dependence, and that he has sought treatment. Such conduct indicates that Joseph Martin Rukse, Jr. falls within the ambit of Sections 3719.121(A) and 4729.16(A)(3) of the Ohio Revised Code. (3) Joseph Martin Rukse, Jr. was convicted on or about November 1, 2000, in the United States District Court for the Southern District of West Virginia of 18 U.S.C. § 1347 (defrauding a health care benefit program) and 21 U.S.C. § 843(a)(3) (acquire a controlled substance by deception). United States of America v. Joseph M. Rukse, Jr., Criminal Action No. 3:00-00219. Such conduct indicates that Joseph Martin Rukse falls within the ambit of Section 3719.121(C) of the Ohio Revised Code. (4) Joseph Martin Rukse, Jr. did, on various dates during the year 2000, violate his Board-Ordered probation, to wit: Joseph Martin Rukse, Jr. was placed on probation for three years by Board Order dated May 5, 1999. The Board suspended his license for forty-two months, but stayed thirty-six months on condition that he violate no drug laws. Paragraphs (2) and (3) above indicate that Joseph Martin Rukse, Jr. violated his probation.
	CONCLUSIONS OF LAW (1) The State Board of Pharmacy concludes that paragraph (3) of the Findings of Fact constitutes being guilty of a felony and gross immorality as provided in Division (A)(1) of Section 4729.16 of the Ohio Revised Code. (2) The State Board of Pharmacy concludes that paragraph (3) of the Findings of Fact constitutes being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code. (3) The State Board of Pharmacy concludes that paragraph (2) of the Findings of Fact constitutes being addicted to or abusing liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy as provided in Division (A)(3) of Section 4729.16 of the Ohio Revised Code.
	DECISION OF THE BOARD Pursuant to Section 3719.121 of the Ohio Revised Code, the State Board of Pharmacy hereby removes the Summary Suspension Order issued to Joseph Martin Rukse, Jr. on December 26, 2000. Pursuant to Section 4729.16 of the Ohio Revised Code, and after consideration of the record as a whole, the State Board of Pharmacy hereby suspends indefinitely the pharmacist identification card, No. 03-2-15318, held by Joseph Martin Rukse, Jr. and such suspension is effective as of the date of the mailing of this Order.
	(A) Joseph Martin Rukse, Jr., pursuant to Rule 4729-9-01(F) of the Ohio Administrative Code, may not be employed by or work in a facility licensed by the State Board of Pharmacy to possess or distribute dangerous drugs during such period of suspension. (B) Joseph Martin Rukse, Jr., pursuant to Section 4729.16(B) of the Ohio Revised Code, must return his identification card and license (wall certificate) to the office of the State Board of Pharmacy within ten days after receipt of this Order unless the Board office is already in possession of both. The identification card and wall certificate should be sent by certified mail, return receipt requested.
	Further, after December 31, 2004, the Board will consider any petition filed by Joseph Martin Rukse, Jr. for a hearing, pursuant to Ohio Revised Code Chapter 119., for reinstatement. The Board will only consider reinstatement of the license to practice pharmacy in Ohio if the following conditions have been met:
	(A) Joseph Martin Rukse, Jr. must take and pass the Multistate Pharmacy Jurisprudence Examination (MPJE) or an equivalent examination approved by the Board (B) Joseph Martin Rukse, Jr. must enter into a contract, signed within thirty days after the effective date of this Order, with an Ohio Department of Alcohol and Drug Addiction Services (ODADAS) treatment provider or a treatment provider acceptable to the Board for a period of not less than five years and, upon signing, mail a copy of the contract to the Board office. The contract must provide that:
	(1) Random, observed urine drug screens shall be conducted at least once each month.
	(a) The urine sample must be given within twelve hours of notification. The urine drug screen must include testing for creatinine or specific gravity of the sample as the dilutional standard. (b) Results of all drug screens must be negative. Any positive results, including those which may have resulted from ingestion of food, but excluding false positives which resulted from medication legitimately prescribed, indicates a violation of the contract.
	(2) Attendance is required a minimum of three times per week at an Alcoholics Anonymous, Narcotics Anonymous, and/or similar support group meeting. (3) The program shall immediately report to the Board any violations of the contract and/or lack of cooperation.
	(C) Joseph Martin Rukse, Jr. must demonstrate satisfactory proof to the Board that he is no longer addicted to or abusing drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy. (D) Joseph Martin Rukse, Jr. must provide, at the reinstatement petition hearing, documentation of the following:
	(1) Compliance with the contract required above (e.g.-proof of giving the sample within twelve hours of notification and copies of all drug screen reports, meeting attendance records, treatment program reports, etc.); (2) Compliance with the continuing pharmacy education requirements as set forth in Chapter 4729-7 of the Ohio Administrative Code as applicable and in effect on the date of petitioning the Board for reinstatement (i.e.-CEUs must be obtained during the three years immediately preceding the petition hearing); (3) Compliance with the terms of this Order.
	(E) If reinstatement is not accomplished within three years of the effective date of this Order, Joseph Martin Rukse, Jr. must also show successful completion of the NAPLEX examination or an equivalent examination approved by the Board. THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY. MOTION CARRIED. SO ORDERED. The motion was seconded by Mrs. Gregg and approved by the Board (Aye-6/Nay-2).
R-2003-196	Ms. Eastman then moved that the Board adopt the following Order in the matter of Matthew Donavon Nourse: ORDER OF THE STATE BOARD OF PHARMACY (Docket No. D-020806-003) In The Matter Of: MATTHEW DONAVON NOURSE, R.Ph. 1054 Graham Lane Lucasville, Ohio 45648 (R.Ph. No. 03-1-22575)
	INTRODUCTION THE MATTER OF MATTHEW DONAVON NOURSE CAME FOR HEARING ON JUNE 3, 2003, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; LAWRENCE J. KOST, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph. MATTHEW DONAVON NOURSE WAS REPRESENTED BY DAVID W. GRAUER AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.
	SUMMARY OF EVIDENCE State’s Witnesses 1. Todd Zevchik, R.Ph., Ohio State Board of Pharmacy Respondent's Witnesses 1. Matthew Donavon Nourse, R.Ph., Respondent
	State's Exhibits 1. Copy of Summary Suspension Order/Notice of Opportunity For Hearing letter [08-06-02] 1A-1F. Procedurals 2. Written Statement of Shirley R. Leslie [07-17-02] 3. Sixteen Accountability Statements completed at Rite Aid #4708 for the following drugs: hydrocodone bit./APAP 10/650 mg, hydrocodone bit./APAP 5/500 mg, hydrocodone bit./APAP 7.5/500 mg, hydrocodone bit./APAP 7.5/750 mg, Vicodin ES 7.5/750 mg, Vicoprofen 7.5/200 mg, lorazepam 0.5 mg, lorazepam 1 mg, lorazepam 2 mg, Xanax 1 mg, alprazolam 1 mg, diazepam 10 mg, diazepam 2 mg, diazepam 5 mg, Valium 10 mg, and Valium 5 mg [05-13-03] 4. Summary of Unauthorized Prescriptions for Matthew Nourse, Rx # 40875 [09-14-99]; Rx # 41719 [09-27-99]; Rx # 43201 [10-16-99]; Rx # 48198 [01-03-00]; Rx # 48878 [01-12-00]; Rx # 48879 [01-12-00]; Rx # 60266 [07-04-00]; Rx # 63323 [08-22-00]; Rx # 66607 [10-08-00]; Rx # 70745 [12-04-00]; Rx # 79286 [03-26-01]; Rx # 81299 [04-23-01], Rx # 82565 [06-11-01], Rx # 98619 [01-09-02]; Rx # 98814 [01-09-02]; Rx # 99315 [01-17-02] 5. Copy of Statement of Matt Nourse [04-15-99]. 6. Copy of letter from Dr. James Baber, M.D. to Wal-Mart Corporation [07-22-99], Drug Screen Report re Matthew Nourse [04-02-99] 7. DEA Report of Theft of Loss of Controlled Substances of Wal-Mart Pharmacy 10-1564 [05-10-99] 8. Official Report, New Boston Police Department, Report No. OR 04-15-991497 [04-16-99] 9. Village of New Boston Case Worksheet for WalMart vs. Nourse, Matthew D., Case No. 99CRB76A [04-26-99] 10. Restitution Note from Matthew D. Nourse to Wal-Mart Stores, Inc. [04-15-99]
	Respondent's Exhibits A. Copy of PRO Pharmacist’s Recovery Contract for Matthew D. Nourse [09-09-02] B. Copy of Support Group Attendance Records [07-30-02 to 05-01-03] C. Copy of Drug Screen Reports [12-20-02 to 05-20-03] D. Letter from Steven R. Welton, R.Ph. [05-14-03] E. Letter from William Basedow, D.O. [05-04-03] F. Letter from James R. Mullins, M.D. [12-19-02] G. Letter from Kevin Gahm, R.Ph. [05-13-03] H. Letter from Sean Higbee, R.Ph. [05-05-03] I. Copy of Certificate of Completion for Matthew Nourse [09-24-02] J. Letter from Adam Kennard, CCDC I [05-27-03]
	FINDINGS OF FACT After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to be fact:
	(1) Records of the State Board of Pharmacy indicate that Matthew Donavon Nourse was originally licensed by the State of Ohio as a pharmacist on August 20, 1997, pursuant to examination, and that his license to practice pharmacy in Ohio was summarily suspended effective August 6, 2002. (2) Matthew Donavon Nourse is addicted to liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy, to wit: on July 16, 2002, while working at Rite Aid Pharmacy #4708, Matthew Donavon Nourse was observed slurring his words, swaying back and forth while standing, and having difficulty keeping his eyes open. A technician stated Matthew Donavon Nourse had made several mistakes processing prescription medication orders, and that he was moving very slowly and seemed extremely tired. Matthew Donavon Nourse admitted that his problems with drugs and alcohol began approximately two years ago, and that he had a drug dependency problem and wanted to get some help. Matthew Donavon Nourse admitted that he had consumed six Vicodin 5/500 mg tablets, an unknown amount of Darvocet-N 100 mg, and one Ativan 0.5 mg tablet. Such conduct indicates that Matthew Donavon Nourse is addicted to the use of controlled substances within the meaning of Section 3719.121 of the Ohio Revised Code. (3) Matthew Donavon Nourse did, on or about July 16, 2002, while employed as a pharmacist for Rite Aid Pharmacy #4708, with purpose to deprive, knowingly obtain or exert control over dangerous drugs, the property of Rite Aid Pharmacy #4708, beyond the express or implied consent of the owner, to wit: Matthew Donavon Nourse has admittedly stolen 6 Vicodin 5/500 mg tablets and an unknown amount of Darvocet-N 100 mg tablets. Such conduct violates Section 2913.02 of the Ohio Revised Code. (4) Matthew Donavon Nourse was convicted, on or about April 30, 1999, of Petty Theft. Walmart vs. Nourse, Matthew D., Case No. 99CRB76A, Village of New Boston Mayor's Court. Such conduct indicates that Matthew Donavon Nourse falls within the ambit of Section 4729.16(A)(4) of the Ohio Revised Code.
	CONCLUSIONS OF LAW (1) The State Board of Pharmacy concludes that paragraphs (2) and (3) of the Findings of Fact constitute being guilty of gross immorality as provided in Division (A)(1) of Section 4729.16 of the Ohio Revised Code. (2) The State Board of Pharmacy concludes that paragraphs (2) and (3) of the Findings of Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code. (3) The State Board of Pharmacy concludes that paragraph (2) of the Findings of Fact constitutes being addicted to or abusing liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy as provided in Division (A)(3) of Section 4729.16 of the Ohio Revised Code. (4) The State Board of Pharmacy concludes that paragraph (4) of the Findings of Fact constitutes being convicted of a misdemeanor related to, or committed in, the practice of pharmacy as provided in Division (A)(4) of Section 4729.16 of the Ohio Revised Code.
	DECISION OF THE BOARD Pursuant to Section 3719.121 of the Ohio Revised Code, the State Board of Pharmacy hereby removes the Summary Suspension Order issued to Matthew Donavon Nourse on August 6, 2002. Pursuant to Section 4729.16 of the Ohio Revised Code, and after consideration of the record as a whole, the State Board of Pharmacy hereby suspends indefinitely the pharmacist identification card, No. 03-1-22575, held by Matthew Donavon Nourse and such suspension is effective as of the date of the mailing of this Order.
	(A) Matthew Donavon Nourse, pursuant to Rule 4729-9-01(F) of the Ohio Administrative Code, may not be employed by or work in a facility licensed by the State Board of Pharmacy to possess or distribute dangerous drugs during such period of suspension. (B) Matthew Donavon Nourse, pursuant to Section 4729.16(B) of the Ohio Revised Code, must return his identification card and license (wall certificate) to the office of the State Board of Pharmacy within ten days after receipt of this Order unless the Board office is already in possession of both. The identification card and wall certificate should be sent by certified mail, return receipt requested.
	Further, after July 31, 2004, the Board will consider any petition filed by Matthew Donavon Nourse for a hearing, pursuant to Ohio Revised Code Chapter 119., for reinstatement. The Board will only consider reinstatement of the license to practice pharmacy in Ohio if the following conditions have been met:
	(A) Matthew Donavon Nourse must obtain, within sixty days after the effective date of this Order, a full psychiatric or psychological evaluation by a licensed psychiatrist or psychologist and must abide by the treatment plan as designed by that psychiatrist or psychologist. The psychiatrist or psychologist must provide an initial status report, which includes the recommended treatment plan, to the Board within ten days after completing the assessment. (B) Matthew Donavon Nourse must enter into a contract, signed within thirty days after the effective date of this Order, with an Ohio Department of Alcohol and Drug Addiction Services (ODADAS) treatment provider or a treatment provider acceptable to the Board for a period of not less than five years and, upon signing, mail a copy of the contract to the Board office. The contract must provide that:
	(1) Random, observed urine drug screens shall be conducted at least once each month. (a) The urine sample must be given within twelve hours of notification. The urine drug screen must include testing for creatinine or specific gravity of the sample as the dilutional standard. (b) Alcohol must be added to the standard urine drug screen. A Breathalyzer may be used to test for alcohol, but the test must be conducted by an appropriately certified individual within twelve hours of notification. (c) Results of all drug and alcohol screens must be negative. Any positive results, including those which may have resulted from ingestion of food, but excluding false positives which resulted from medication legitimately prescribed, indicates a violation of the contract.
	(2) Attendance is required a minimum of three times per week at an Alcoholics Anonymous, Narcotics Anonymous, and/or similar support group meeting. (3) The program shall immediately report to the Board any violations of the contract and/or lack of cooperation.
	(C) Matthew Donavon Nourse must demonstrate satisfactory proof to the Board that he is no longer addicted to or abusing liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy. (D) Matthew Donavon Nourse must provide, at the reinstatement petition hearing, documentation of the following:
	(1) Payment of any outstanding restitution or have an approved payment plan. (2) Notify his current employer of his addiction to drugs and alcohol and have his employer respond to the Board of receiving such notification. (3) Compliance with the licensed psychiatrist's or psychologist's recommended treatment plan; (4) A report by the licensed psychiatrist or psychologist regarding Matthew Donavon Nourse's fitness for readmission into the practice of pharmacy; (5) Compliance with the contract required above (e.g.-proof of giving the urine sample within twelve hours of notification and copies of all drug and alcohol urine screen reports, meeting attendance records, treatment program reports, etc.); (6) Compliance with the continuing pharmacy education requirements set forth in Chapter 4729-7 of the Ohio Administrative Code as applicable and in effect on the date of petitioning the Board for reinstatement; (7) Compliance with the terms of this Order.
	(E) If reinstatement is not accomplished within three years of the effective date of this Order, Matthew Donavon Nourse must also show successful completion of the NAPLEX examination or an equivalent examination approved by the Board. THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY. MOTION CARRIED. SO ORDERED. The motion was seconded by Mr. Turner and approved by the Board (Aye-8/Nay-0).

2.55 p.m.

Mr. Braylock reported on the Nursing Board’s Committee on Prescriptive Governance meeting of April 28, 2003.

3:05 p.m.

The meeting recessed until Wednesday, June 4, 2003.

WEDNESDAY, JUNE 4, 2003

8:30 a.m.

ROLL CALL

The State Board of Pharmacy convened in Room West-B&C, 31st Floor, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio with the following members present:

Diane C. Adelman, R.Ph. (President); Robert P. Giacalone, R.Ph. (Vice-President); Suzanne R. Eastman, R.Ph.; Elizabeth I. Gregg, R.Ph.; Lawrence J. Kost, R.Ph.; Nathan S. Lipsyc, R.Ph.; Dorothy S. Teater, Public Member; and James E. Turner, R.Ph.

8:31 a.m.

Mrs. Teater gave a report on the pharmacists who currently are on probation with the Board. There were no issues requiring official action by the Board.

8:32 a.m.

Board Member Gregory Braylock, R.Ph. arrived.

9:25 a.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Abdallah D. Abukhalil, R.Ph., Cleveland.

11:48 a.m.

The hearing ended and the record was closed. The Board took a brief recess.

11:57 a.m.

Mrs. Gregg moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code. The motion was seconded by Mr. Lipsyc and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.

12:50 p.m.

R-2003-197	The Executive Session ended and the meeting was opened to the public. Mr. Kost moved that the Board adopt the following Order in the matter of Abdallah D. Abukhalil: ORDER OF THE STATE BOARD OF PHARMACY (Docket No. D-020514-057) In The Matter Of: ABDALLAH D. ABUKHALIL, R.Ph. 16544 North White Oaks Drive Strongsville, Ohio 44136 (R.Ph. No. 03-3-23964)
	INTRODUCTION THE MATTER OF ABDALLAH D. ABUKHALIL CAME FOR HEARING ON JUNE 4, 2003, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; LAWRENCE J. KOST, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph. ABDALLAH D. ABUKHALIL WAS REPRESENTED BY ELIZABETH Y. COLLIS AND JOSEPH A. DUBYAK AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.
	SUMMARY OF EVIDENCE State’s Witnesses None Respondent's Witnesses 1. Abdallah D. Abukhalil, R.Ph., Respondent 2. Andrew Sperling, R.Ph.
	State's Exhibits 1. Copy of Notice of Opportunity For Hearing letter [05-14-02] 1A-1H. Procedurals 2. Indictment, State of Ohio vs. Abdalah Abukhalil, Case No. CR 389148, Cuyahoga County Common Pleas Court [03-30-00] 3. Journal Entry of Plea [06-12-01] 4. Journal Entry of Sentencing [07-30-01] 5. Copy of Report of Investigation [12-31-99] and three Follow-up Investigation reports [01-04-00, 01-07-00, and 01-18-00], Incident No. 55899, Cleveland Fire Department 6. Copy of Statement of Debbie Smith [01-14-00] 7. Copy of Statement of Latoya Mitchell [01-14-00] 8. Copy of Statement of Carrie James [01-18-00]
	Respondent's Exhibits A. Copy of Revco Pharmacist Performance Evaluation Form re Abdallah Abukhalil [July 2001 to July 2002] B. Copy of Dangerous Drug Distributor Inspection Report for CVS Pharmacy #4803 [01-16-02] C. Letter from Ziad Malzoum and Andy Sperling [09-23-02] E. Letter from Fred H. Schill [09-30-02] F. Copy of letter from Steve Barney, R.Ph. [10-15-02] G. Copy of letter from Baltek S. Randbawa, R.Ph. [10-03-02] H. Copy of Journal Entry of Sentencing, State of Ohio vs. Abdalah Abukhalil, Case No. CR389148, Cuyahoga County Common Pleas Court [07-30-01] I. Copy of Motion To Terminate Probation [01-03-03] J. Copy of Journal Entry of Decision [03-19-03] K. Copy of Stipulated Dismissal Entry, State Farm Fire & Casualty Company, et al vs. Mohammahd D. Mohammad, et al, Case No. CR448882, Cuyahoga County Common Pleas Court [01-08-03] L. Copy of Release Of All Claims Form re Abdallah Abukhalil [11-21-02] M. Copy of University of Florida Proof of Enrollment Form re Abdallah Abukhalil [not dated] N. Copies of Continuing Pharmaceutical Education Certificates [01-26-01 to 02-20-02]
	FINDINGS OF FACT After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to be fact:
	(1) Records of the State Board of Pharmacy indicate that Abdallah D. Abukhalil was originally licensed by the State of Ohio as a pharmacist on February 11, 2000, pursuant to examination, and is currently licensed to practice pharmacy in Ohio. (2) On June 5, 2001, Abdallah D. Abukhalil pled no contest to Arson, a fourth degree felony under Section 2909.03 of the Ohio Revised Code. State of Ohio vs. Abdalah Abukhalil, Case No. 389148, Cuyahoga County Common Pleas Court.
	CONCLUSION OF LAW The State Board of Pharmacy concludes that paragraph (2) of the Findings of Fact constitutes being guilty of a felony and gross immorality as provided in Division (A)(1) of Section 4729.16 of the Ohio Revised Code.
	DECISION OF THE BOARD Pursuant to Section 4729.16 of the Ohio Revised Code, and after consideration of the record as a whole, the State Board of Pharmacy hereby revokes the pharmacist identification card, No. 03-3-23964, held by Abdallah D. Abukhalil effective as of the date of the mailing of this Order. Pursuant to Section 4729.16(B) of the Ohio Revised Code, Abdallah D. Abukhalil must return his identification card and license (wall certificate) to the office of the State Board of Pharmacy within ten days after receipt of this Order unless the Board office is already in possession of both. The identification card and wall certificate should be sent by certified mail, return receipt requested. THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY. MOTION CARRIED. SO ORDERED. The motion was seconded by Ms. Eastman and approved by the Board (Aye-4/Nay-3/Abstain-1[Lipsyc]).

12:52 p.m.

Mr. Benedict presented a press release from the Department of Health regarding initiation of the Pharmaceutical Case Management program.

12:55 p.m.

Mrs. Gregg moved that the Board receive Per Diem as follows:

PER DIEM	4/28	6/2	6/3	6/4	Total
Adelman	-	1	1	1	3
Braylock	1	1	1	1	4
Eastman	-	1	1	1	3
Giacalone	-	1	1	1	3
Gregg	-	1	1	1	3
Lipsyc	-	1	1	1	3
Kost	-	1	1	1	3
Teater	-	1	1	1	3
Turner	-	1	1	1	3

The motion was seconded by Mr. Lipsyc and approved by the Board (Aye-8/Nay-0).

12:58 p.m.

Mr. Lipsyc moved that the meeting be adjourned. The motion was seconded by Mrs. Gregg and approved (Aye-8/Nay-0).

THE BOARD APPROVED THESE MINUTES

JULY 15, 2003